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This dissertation reviews the development and implementation of integrative, 
systems biology methods designed to parse driver mutations from high-
throughput array data derived from human patients. The analysis of vast 
amounts of genomic and genetic data in the context of complex human genetic 
diseases such as Glioblastoma is a daunting task. Mutations exist by the 
hundreds, if not thousands, and only an unknown handful will contribute to the 
disease in a significant way. The goal of this project was to develop novel 
computational methods to identify candidate mutations from these data that drive 
the molecular differentiation of glioblastoma into the mesenchymal subtype, the 
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Glioblastoma (GBM), the most prevalent brain cancer found in humans[30]][35], is 
an undoubtedly complex genetic disease. Along with other fields of cancer study, 
recent research is beginning to reveal the extent of physiological variability in 
tumors affecting different patients. Although GBM tumors share traits common 
enough to be classified under the same umbrella term (such as basic histological 
markers), there is significant variability in other traits associated with the patient’s 
prognosis; the aggressiveness of the tumor, its metastasis, and its resistance to 
therapeutics are not uniform in GBM. At both genomic and genetic levels, GBM 
tumors are as heterogeneous as their physiology suggests[3][5][32][42]. A GBM 
tumor does not develop solely with the activation of oncogenic driver[48]; although 
this is a necessary and essential step, tumors exhibit the concomitant, large-
scale genomic alterations that result in GBM tumors differentiating into three 
molecularly distinct subtypes: the Mesenchymal, Proneural, and Proliferative 
subtypes. The Mesenchymal subtype earmarks specific physiological behaviors 
of the tumor that exist independently of oncogenic processes and uniquely affect 
the prognosis associated with the disease: mesenchymal GBM are the most 
aggressively growing, poorest prognosis GBM tumors[31][35]. 
 
This finding corroborates the notion that GBM, and cancers by extension, are not 
diseases resulting solely from the activation of oncogenic processes. There are 
other physiological, developmental, and molecular processes that are regulated 
independently of oncogenesis, yet contribute significantly to the overall behavior 
of the disease. It is equally important to the understanding of GBM biology to 
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characterize the genetic regulation of these other processes, and how their co-
occurrence with oncogenic mutations can alter the progression of GBM. This is 
not straightforward when studying a disease characterized by hundreds, if not 
thousands, of genomic mutations co-occurring in a single patient. Mutations 
occur in different patterns that can render every single GBM patient unique from 
another[71].  
 
The goal of this work was to develop a computational framework that 
integrates several sources of high-throughput data and systems biology 
approaches to predict the driver mutations that induce Mesenchymal 
differentiation in Glioblastoma. Molecular perturbations that result in 
mesenchymal differentiation should correlate with the genomic mutations 
that are responsible for their aberrant expression, and these perturbations 
can be used to reverse engineer the genomic-genetic integration. 
 
Glioblastoma and the Mesenchymal Subtype: a Molecular Perspective 
Glioblastoma (GBM) is a subcategory of high-grade gliomas, the most common 
type of brain tumors found in humans. Over 50% of brain tumors in functional 
brain tissue of human patients are classified into this category[35]. There is a 
slightly higher incidence in males, and the average age of onset is >50[31]. Brain 
cancers are pathologically identified as GBM based primarily on the presence of 
necrotic or necrotizing tissue at the core of the tumor, surrounded by anaplastic 
(un- or de-differentiated cells) and typically an extensive vasculature[2][23][57]. 
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These cancers are virtually incurable and highly aggressive. The average post-
diagnosis survival of patients is projected as twelve months with treatment, and 
typically less than four months without treatment[46]. They are extremely difficult 
to detect, and are typically only identified later in the cancer progression due to 
the presentation of secondary symptoms: the tumor develops large enough in 
size to cause increased intracranial pressure, impairment of neural and cognitive 
function, and other generalized symptoms such as chronic headaches, nausea, 
etc. Furthermore, GBM has displayed a robust resistance to standard cancer 
therapeutics in addition to the naturally dangerous risks of treating diseases in 
the brain[46] [51] [53]. Transporting drugs across the blood brain barrier has always 
been a difficult medical procedure, and tumor resections in the brain carry the 
inherent risk of causing irrevocable secondary damage. 
 
At a genetic level, GBM is a disease characterized by significant de novo somatic 
chromosomal copy changes and rearrangements, and there are subsequently no 
known hereditary risk factors[22]. There are also no significant associations of 
brain cancer with specific environmental factors[46]. These tumors typically 
present with genomic alterations in “classic” oncogenic drivers and tumor 
suppressors: amplifications of EGFR[63][68][71] or losses of p16[24] are found in over 
60% of patients, and typically in combination[67][68]. Despite the significant 
mutation rate of oncogenic genes, the variable rates of these mutations 
combined with extensive mutations throughout the genome establish GBM as a 
highly heterogeneous genetic disease. While a large number of patients may 
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bear mutations at the EGFR or p16 loci, each patient exhibits evidence for 
chromosomal alterations affecting hundreds to thousands of other genes in 
unique and unpredictable combinations. This results in a genetically and 
physiologically diverse cancer, which, in combination with the resistance of GBM 
to conventional therapeutics, has led the field to begin refining our definitions of 
GBM in order to improve our understanding of the mechanics and etiology of this 
complex genetic disease.  
 
In the past, the study of cancer in general focused primarily on the identification 
of genetic variants and genomic loci that predispose or induce tumor formation, 
such as EGFR and p16. Genes whose increased expression leads to 
tumorigenesis are called oncogenes, and genes whose loss induces 
tumorigenesis, tumor suppressors. Tumor suppressors and oncogenes are 
typically genes participating in key developmental pathways, such as the Notch 
and Wnt signaling cascades[47][67][70], or metabolic and cellular proliferation 
pathways[79]. Aberrant activation or re-activation of these developmental 
pathways trigger unchecked, accelerated proliferation that could lead to 
formation of tumor masses, differentiation or de-differentiation that could result in 
metastasis, and the co-opting of “normal” biological processes such as 
angiogenesis to provide nutrients for the growing mass.  
 
These genetic elements are typically insufficient individually to induce the full 
development of cancer, but subsequent studies identified that a series of 
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accumulated genetic abnormalities could push cells into tumorigenic behavior. 
Cancer has been shown, along these lines, to be a complex genetic disease 
requiring the input of multiple genetic processes to fully develop into the unique 
pathogenic tumors and metastases. In cancers like GBM, this coincides with the 
diverse genomic mutation architecture observed in patients. However, prior to the 
development of high-throughput genetic and genomic screening, candidate-
based approaches have primarily been used to make sense of how individual 
mutations and biological processes contribute to the disease. 
 
The availability and cost-
effectiveness of gene expression 
profiling has increased 
significantly in recent years, 
allowing for new means of 
defining cancers such as GBM at 
the molecular level. Numerous 
studies have been conducted that 
indicate that cancers that have 
been presumed to be a single 
disease actually segregate into 
distinct molecular 
subtypes[32][42][52][59]. While a great deal of research has been focused on 
understanding the oncogenic drivers and oncogenic and angiogenic properties of 
Figure legend: Unsupervised hierarchical clustering of genes 
whose expression correlated with patient prognosis in GBM 
revealed three distinct, mutually exclusive molecular subtypes. 
The Mesenchymal, Proneural, and Proliferative subtypes were 
coined after the expression of marker genes that canonically 
define mesenchyme, proneural tissue, and cellular proliferation 
processes, respectively. The mesenchymal expression profile 
in particular was associated specifically with poorest patient 
prognosis, and the proneural signature with the best. 
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GBM, it has also become apparent that the heterogeneity of GBM has 
ramifications that extend far beyond the “classic” tumorigenic pathways. The 
umbrella classification of Glioblastoma itself contains an amalgamation of 
molecularly and physiologically distinct brain tumors that bear extensive, yet 
unique, profiles of mutated genes, and equally diverse distributions of unique 
patterns of gene expression. Research on the unique expression patterns of 
various GBM samples has revealed that brain tumors falling under the umbrella 
classification of “Glioblastoma” cosegregate into three distinct subtypes, which 
were coined the Mesenchymal (MES), Proneural (PN), and Proliferative (PRO) 
subtypes[52]. Each subtype was named and defined based upon the expression 
of gene markers primarily expressed in mesenchyme (YKL40, FN1), in tissues of 
neural and proneural origin (OLIG2, BCAN), and upon activation of cellular 
proliferation and angiogenesis (TOP2A, PCNA), respectively. Phillips et al. 
reported that the expression of these three marker panels is mutually exclusive: 
MES samples both express MES markers and show suppression of PN and PRO 
markers. Moreover, GBM subtypes do not show any significant correlation with 
classical oncogenic mutations. 
 
Further analysis revealed that tumors expressing the MES expression signature 
are at maximal risk of being highly aggressive, even more so than other GBM 
tumors, and predictive of the poorest prognosis in the overall patient cohort. It 
was hypothesized that the expression of MES markers contributes to the 
alteration of the tumor’s biology, rendering it highly aggressive and resistant to 
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treatment, though the particular mechanics behind the contribution to poor 
prognosis are unknown. It was proposed that the MES expression pattern is a 
quantitative molecular predictor of the poorest prognosis GBM that warranted 
further study. This profile could also be used as a biological readout for poor 
prognosis tumors in subsequent experiments instead of relying on more noisy, 
indirect, and qualitative measures such as World Health Organization grade and 
prognosis. 
 
Studies such as these have allowed the field to model GBM as a molecular 
disease, rather than a “physiological” one. “GBM tumors” that exhibit behaviors 
across a general spectrum can now be broken down into a series of discrete 
expression profiles. Each set of genes in an expression profile could provide 
insight into the precise genetic pathways that are required to develop a specific 
subtype of GBM. Even more specifically, it was shown that distinct subtypes of 
cancers exist beyond what could medically be distinguished by histology and 
other clinical assays. These molecular subtypes also provided an explanation as 
to why different patients responded drastically differently to both the disease and 
treatments: the diseases being treated as the same were not the same. The 
focus of research for many shifted to understanding how to integrate this 
molecular information into modeling GBM for both an understanding of its 
etiology, and potential development of more focused, effective treatments. 
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Concurrently, The Cancer Genome Atlas (TCGA) had launched a massive 
initiative to gather and catalogue patient-matched clinical, gene expression, 
genomic, and DNA sequencing data on tumor samples obtained from patients 
around the world. The objective was to gather this large-scale data and make it 
publicly available to researches, providing an enormous sample pool of data that 
would be daunting and impractical, if not impossible, for any individual researcher 
to attempt to gather alone[67][68]. We were able to obtain gene expression, gene 
copy number, and clinical annotation data on 252 GBM tumors from human 
patients to complement the work of Phillips et al. This amalgamation of data 
provided a unique opportunity and resource with sufficient power to study the 
molecular and genetic regulation of the differentiation of these three subtypes of 
GBM with systems biology approaches geared towards understanding the 
regulation of large-scale molecular phenotypes. 
 
Systems Biology Approaches and MES Master Regulators  
In order to place my work into the context of a specific systems biology approach, 
it is important to understand how the Califano lab as a whole approaches 
problems such as MES subtype differentiation. We specifically sought to further 
understand the biology of the MES subtype GBM by attempting to identify the 
genetic regulators that drive the activation of the MES marker panel. The more 
traditional bioinformatic approach is to identify key expression patterns in the 
tumor and isolate developmental or metabolic pathways for further 
characterization and study[21][23]. When the expression of angiogenic regulators is 
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discovered amidst a panel of differentially expressed genes when compared to 
“normal” control tissue, research is then geared towards specifically targeting 
aberrant angiogenesis[66]. While this has produced fruitful research, a 
fundamental limitation exists in the approach. It is not designed to elucidate 
novel, important processes or genetic regulators, and only accounts for a 
relatively arbitrary selection of candidate genes with already-known or implied 
functions in a cancer such as GBM. Furthermore, fundamental assumptions are 
made in candidate selection that are not necessarily true. It is assumed that there 
exists one gene, or relatively few genes, that cause the phenotype. It is assumed 
that these genes are differentially expressed at a statistically detectable level, 
and that all other genes that are differentially expressed are either unrelated or 
downstream consequences of the select few drivers. While any of these can be 
true, none can be assumed a priori when doing genome-wide, array-based 
studies for the selection of causal contributors to the disease.  
 
Instead, the Califano lab employed a systems biology approach to understanding 
subtype differentiation in GBM. Rather than selecting candidate genes from a 
panel of differentially expressed genes by their involvement with biological 
processes such as oncogenesis and angiogenesis, we used the entire set of 
differentially expressed genes as a phenotypic readout. This is a systemic 
approach used to identify the genetic regulators of an entire expression profile, 
including all of the biological processes that are altered, to account for the 
tumor’s unique behavior in its entirety. This was accomplished by implementing 
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the ARACNe algorithm in the TCGA GBM dataset, a method of reverse-
engineering context-specific transcriptional networks[3][10][11]. 
 
The ARACNe algorithm developed by the Califano lab uses Mutual Information, a 
measure of probabilistic dependency between variables that is capable of 
measuring non-linear and non-monotonic correlations, and an extension of Data 
Processing Inequality (DPI), to infer genetic regulatory interactions directly from 
data with human origins[39][40]. Targets of transcription factors are identified by 
finding genes whose expression has a high degree of correlation via mutual 
information with the expression of a transcription factor. The non-transcription 
factor genes are presumed to be regulatory targets of the transcription factor, 
based on the hypothesis that transcription factors are more likely to regulate 
multiple targets than that targets are regulated by large numbers of transcription 
factors. The DPI is then used to systematically eliminate likely indirect regulatory 
targets to create transcriptional “regulons,” or sets of genes that are specific 
targets of each transcription factor[39]. Using this methodology we have been able 
to reverse engineer context-specific regulatory networks with up to 70% 
validation in contexts such as B-cell lymphoma and GBM[3][11]. This result is 
essentially a transcriptional map of all genes expressed in the analyzed context, 
complete with all transcription factors that are expressed in the tissue and the 
predicted gene targets that they specifically, and directly, regulate. 
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The transcriptional network can subsequently be interrogated to identify “Master 
Regulators,” or MRs, which are transcription factors whose regulons are enriched 
in a molecular gene expression signature that corresponds to a phenotype of 
interest. In doing so, we essentially identify the fewest number of transcription 
factors that would be necessary to specifically recapitulate the observed 
molecular expression phenotype. Interrogating the GBM network for Master 
Regulators of the mesenchymal GBM gene expression signature identified three 
transcription factors: CEBPB, CEBPD, and STAT3[11]. Our results indicated that 
over 70% of the MES gene expression signature panel defined by Phillips et al. 
could be activated by expressing a combination of only these three transcription 
factors.  
 
The biological importance of these findings was established when we observed 
that shRNA-mediated co-silencing of CEBPB/D and STAT3 was sufficient to 
suppress the expression of mesenchymal markers in MES GBM tumor-derived 
cell lines that were intercranially injected into mice. Tumor cells with the co-
silencing of these master regulators did not proliferate and they develop into solid 
masses, whereas individually silenced and un-silenced cells universally 
developed into tumors that were fatal to the mice. Furthermore, the protein 
expression of these three TFs in independent cohorts of human GBM patients 
stratified with the worst patient prognoses in a similar manner: tumors sections 
staining double-positive for CEBP and STAT3 proteins associated with 
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significantly poorer prognoses than in patients that were negative or singly-
positive for these proteins[11]. 
 
These results validated the computational inferences that predicted the CEBPs 
and STAT3 as master regulators specifically for the activation of the 
mesenchymal subtype behavior in GBM. It had become possible to 
computationally model a complex genetic disease as a gene expression 
signature and to predict the master regulators of that signature, thereby 
predicting the genetic regulators of the disease or phenotype of interest. The 
master regulator modules served as a molecular “bottleneck” through which all 
transcriptional and regulatory processes were integrated to produce a specific 
molecular effect. Any genetic event or change that directly or indirectly perturbed 
the behavior of the CEBPs and STAT3 would be predicted to induce 
mesenchymal transformation in GBM. This provided a novel way of approaching 
the study of genetic disease etiology: identifying or predicting the genes that 
regulate the behavior of master regulators allows for more targeted screening 
methods than using genome-wide approaches. In addition, traditional genomic 
approaches introduce confounding factors such as passenger mutations, 
mutations that contribute to unrelated disease behaviors, and they lose valuable 
power to the correction of large numbers of tested statistical hypotheses.  
 
These results also provide support for the notion that clinically relevant 
physiological traits of GBM are dictated by more than the classical oncogenic 
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signaling pathways. Whether by an addiction mechanism or otherwise, molecular 
programs activated in tandem with the classical oncogenic programs can 
contribute to the progression of disease. Equally important is the implication that 
diseases such as GBM can potentially be treated through more molecular 
avenues than the extensively studied oncogenic and angiogenic signaling 
cascades. Understanding the genetic events that drive the expression of these 
unique gene panels, and how they relate to the progression of the disease, is 
becoming as scientifically important as the genetic events that drive the formation 
of tumors, and evidence is mounting that the plethora of mutations that exist 
along with oncogenic mutations cannot be ignored for contribution to cancers 
such as GBM. 
 
Genomic Mutations and eQTLs: a genomic perspective 
My thesis began as a natural extension of this work, and to ask the question: 
what actually happened in the genome of the patients to induce the 
activation of these master regulators? These master regulators have never 
been specifically associated with classical oncogenic drivers in network or 
biological analyses. They have never even been extensively studied in the 
context of GBM, and their role was completely unknown prior to our application of 
ARACNe to the Phillips classification. In a complex disease characterized by 
extensive alteration of its genome, we hypothesized that other mutations 
originally considered as “background” or “passenger” alterations to the more 
prominent oncogenic drivers must have contributed to the differentiation of the 
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distinct molecular subtypes, and we sought a method to identify and validate 
them in the context of mesenchymal GBM.  
 
This idea serves as the conceptual basis for the now-ubiquitous genome-wide 
association studies. A genomic region demarcated by some combination of 
genetic markers, ranging from balancers to microsatellites to restriction length 
polymorphisms, is tested for association to some phenotype. This phenotype can 
be a disease or higher-level trait, or can be the expression of specific proteins 
and markers. For polygenic and complex traits, this typically results in multiple 
regions of the genome associating with the trait, typically including several 
genes; it is hypothesized that some combination of genes in these associated 
regions provide combinatorial contribution to the overall trait being observed. 
However, a common issue that stymies GWAS is the significant degree of 
identifiable mutations or SNPs that exist in any given individual. The sheer 
number of loci that must be tested for association across a cohort requires 
extensive correction for statistical testing in order to pare down the genomic data 
to an interpretable, testable set of candidates. Furthermore, diseases with 
diverse genetic causes prove difficult to parse because the association signals of 
each cause are diluted when comparing against a cohort of patients that include 
other causal genetic variants.  
 
This issue can be addressed by integrating additional information into the 
analytic framework to shorten the list of candidate loci. The introduction and 
 16 
development of sophisticated gene expression studies has made integrating 
gene expression with gene mutation / genotype a promising choice. The concept 
of linking genetics (gene expression, expression patterns) and genomics 
(chromosomal and mutational data) is not a novel one, and is itself an extension 
of studying Quantitative Trail Loci. Mapping Quantitative Trait Loci (QTLs) in 
model organisms was a natural extension of linkage analyses tracing the 
association of linkage markers and polymorphisms associated with polygenic 
traits[36]. Genomic regions associated with genetic markers (SNPs or 
microsatellites, etc) were correlated with gene expression panels obtained while 
studying “quantitative traits,” or traits that do not have canonical Mendelian 
inheritance patterns. These traits were typically binary and discrete, and 
regulated by a minimal number of genes (yellow vs red, on vs off, etc).  
 
An example of a quantitative trait is a person’s height. Human height exists 
across a continuous spectrum of measurements, and no individual “height” gene 
exists that is solely responsible for the regulation of how tall a person can/will 
develop. While there are undoubtedly environmental and developmental 
considerations to be taken for how tall or short an individual will be, height 
regardless tends to show distinct patterns of heritability. A QTL analysis applied 
to this issue would obtain the genotypes of a cohort of human subjects with 
varied height, and genomic loci whose genotype differences were predictive of 
height difference were identified in combination, based on statistical and 
computational methods. Genomic loci that maximized the prediction of height 
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would subsequently be identified as QTLs, loci that contributed to the quantitative 
trait of height. This methodology was not geared towards identifying causal 
genomic loci via identification of specific mutations, but instead to identify by 
linkage and association the genomic loci that appeared to contribute to a 
quantitative state. 
 
While this methodology was originally designed to analyze “organism-level” traits, 
or physiological traits that were directly observable, the advent of genetic and 
molecular profiling and the development of gene expression studies provided a 
molecular extension for this methodology, much in a manner similar to what was 
discussed for GBM and cancer previously. It had become possible to look at how 
genetic markers segregated with the transcriptional behavior of genes- to directly 
correlate gene expression to genotype, rather than looking at the effects of gene 
expression with reference to the genotype. A trait could be redefined as a 
product of the gene expression that drives the trait, which in turn was presumed 
to be regulated at a genomic level in a manner predicted by the genotype[29]. 
 
The development of the “Systems Biology” perspective was readily compatible 
with these approaches. With the increased understanding of transcriptional 
regulation in molecular systems, eQTLs could be modeled and identified by how 
they affect the behavior of major transcriptional regulators in both cis- and trans-
regulatory interactions.  Genetic variants that associated directly with the coding 
regions of major transcription regulators could be linked to the altered expression 
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of the transcription factor itself and / or the behavior of its targets (cis-regulation) 
by adapting more traditional correlative and statistical metrics integrated with 
transcriptional assays and binding assays. Conversely, trans-regulatory elements 
were defined as genetic variants that, while not falling within the coding region of 
a regulator or gene directly, nonetheless directly associated with the altered 
behavior of the gene’s expression. These variants could affect the behavior of 
other genes in a variety of ways. As an example, a variant could fall in a region of 
another gene that regulates the transcription or activity of the gene being, or alter 
the methylation state of the genomic region resulting in silencing or activation. In 
the context of transcriptional regulation, researchers began improving the 
detection of such genetic variants that altered gene activity by integrating 
additional information to maximize a priori knowledge of the predicted function of 
the genes being studied through several different methods.  
 
One approach was to include transcription factor binding information. 
Transcription factors are proteins that regulate the expression of other genes by 
binding to DNA at a coding region to initiate transcription of mRNAs. Each 
transcription factor recognizes a distinct subset of genes and is able to activate 
(or repress) the transcription specifically of these targets. Multiple transcription 
factors can share the same target, but the overlap is variable. A core binding 
sequence defines the specificity of these regulatory regimes. This motif must be 
present in the promoter regions of a gene in order for a transcription factor to 
recognize, bind, and initiate transcription. Subsequently, any gene that is a target 
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of a given transcription factor will bear a binding motif for that transcription factor 
in its promoter region. These motifs and their specific affinities can be 
computationally predicted using a combination of binding assays and 
thermodynamic models. 
 
The availability of genomic sequencing allowed for the searching of promoter 
regions for these binding motifs, and to predict the binding activity based on the 
sequence similarities found in each specific promoter. Integrating this information 
with gene expression allows for an accurate measure of the activity of a 
transcription factor as a function of its transcriptional targets, identified by binding 
motifs. Differential activity across different genotypes could then be used to 
identify genomic regions that co-segregated with the differential activity of each 
transcription factor, defining genomic regions, or aQTLs,  that associate with the 
differential activity of specific transcription factors[6] . 
 
Identifying Driver Mutations by Integrating Master Regulators 
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Our reverse-engineered networks 
and master regulator analysis 
allow us to add an additional, 
pivotal dimension to these 
approaches: the ability to capitalize 
on our molecular “bottleneck” to 
measure the effect of genomic 
mutations on the transcriptional 
activity of master regulators that 
control a specific gene expression 
set. Identifying the mutations that 
control a gene expression set, by 
proxy, implies that the mutations 
control the phenotype associated 
with the expression set. Rather than asking, “What mutations associate with the 
MES phenotype,” I instead ask, “What mutations perturb the molecular behavior 
of the MES master regulators? What mutations are predicted to induce the 
expression of the MES phenotype?” These questions can be answered using an 
algorithm that incorporates transcriptional networks, genomic profiling, and gene 
expression profiling. I set out to develop this algorithm and perform an analysis 
on the TCGA dataset to identify candidate mutations that could drive the 
expression and differentiation of the Mesenchymal subtype, and biologically 
validate any subsequent results. Candidate mutations were expected to 
Algorithms such as ARACNe and MINDy have 
identified molecular “bottlenecks,” small modules 
of master regulators and modulators that integrate 
signals required to activate the expression of 
gene expression profiles that define and 
potentially drive cancer subtype differentiation. 
We hypothesize that the genomic mutations that 
drive the differentiation, subsequently, must in 
some way interact with the master regulator 
bottleneck- a small number of master regulators 
regulate a large gene panel, and genomic 
mutations that drive the phenotype must interact 
with the master regulators. 
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specifically perturb, directly or indirectly, the molecular behavior of the CEBP and 
STAT3 master regulators. 
 
In my case, GBM was considered the ideal model to develop an algorithm to link 
genomic mutations to regulatory network perturbations (and subsequently gene 
expression profiles) due to the availability of patient-matched data through the 
TCGA. This matched data allowed us to classify GBM samples, reconstruct the 
GBM transcriptional network and interrogate for subtype master regulators, and 
finally attempt to integrate genomic information all in the same patient cohort to 
establish causality between mutations and molecular behaviors within patient 
samples. 
 
This thesis details the development, implementation, and validation of my genetic 
genomic analytic framework in the following steps, broken down by chapter: 
 
Chapter 2: Identifying mesenchymal cohorts in the TCGA dataset and selecting 
optimal parameters for downstream analysis. 
 
Chapter 3: The definition of functional CNVs and parsing them from genomic and 
genetic data. 
 
Chapter 4: Picking candidate driver mutations of the MES subtype using 
conditional association metrics 
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Chapter 5: A manuscript submitted to Nature on the identification and biological 
validation of the candidate MES driver, KLHL9 
 
Chapter 5a: Additional work-in-progress addressing reviewer comments for the 
manuscript 
 









































At its core, studying the genomic drivers of differentiation to the MES GBM 
subtype requires the integration of several types of data: gene expression, 
genomic status (mutations, copy number, etc), molecular subtype classification, 
and regulatory networks. The functional genetic-genomics algorithm itself 
requires only CNV and gene expression data, but all of these types must be 
available to complete the downstream analyses associated with the entire 
workflow.  
 
While the original subtypes defined by Phillips et al. were defined in a fairly large 
cohort, data generated by TCGA contained independent patient-matched 
genomic and gene expression data across a cohort of >230 patients. This was 
precisely the type and amount of data required for the analyses intended for my 
thesis work, but before any progress could be made in predicting mesenchymal 
drivers, I had to ensure that the TCGA cohort was comparable to the Phillips 
cohort, and that the subtypes could be accurately recapitulated in this 
independent dataset.  
 
Furthermore, none of these resources are standardized to be directly integrated 
into a framework that I had proposed, so prior to actually running and validating 
the analysis, data processing was conducted to ensure that the data made 
available by the TCGA could be formatted and curated to generate biologically 
meaningful results. The details of each step are entailed here. 
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Classifying TCGA GBM Samples 
The first task at hand in analyzing the TCGA dataset was the reclassification of 
patient samples into the MES, PN, and PRO subtypes originally defined by 
Phillips et al. These subtypes exist as user-defined molecular classifications; 
there is no predefined way to directly recapitulate these classifications solely 
from the TCGA data. In order to classify the TCGA samples as closely to the 
original Phillips samples as possible, I opted to build a centroid-based classifier 
that was trained on the Phillips classification and dataset and use this to separate 
the subtypes in the TCGA dataset. This approach allows us to more closely 
match the specific molecular profiles defined by Phillips, instead of attempting a 
new hierarchical classification in the TCGA set alone using the Phillips marker 
panels. 
 
I selected three markers to represent each subtype (nine markers total), which 
were chosen by two criteria: the genes were not transcription factors and had the 
highest coefficient of variation between the samples. The markers selected by 
these criteria were: YKL40, SERPINE1, and TIMP1 for the MES signature; 
BCAN, OLIG2, and KLRC3 for the PN signature; and HMMR, TOP2A, and PCNA 
for the PRO signature. A centroid representing each Phillips subtype was created 
using the nine markers by defining a point in the search space with minimal 
average Euclidean distance between all samples of a single subtype in the 
Phillips dataset. These parameters were then used on the incoming TCGA 
samples for classification. Each TCGA sample was classified as the subtype of 
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the nearest centroid, again measured by Euclidean distance.  I selected markers 
that were not transcription factors to remove the possibility of bias in subsequent 
analyses that are informed by transcription regulatory networks; training a 
classifier on a transcription factor will artificially increase the enrichment of its 
regulon in patient samples when a transcription regulatory network is 
interrogated. Maximizing the coefficients of variation allowed for the selection of 
the minimum number of markers while maximizing their information, ensuring 
that I did not overfit our classification by using excessively large marker panels. 
 
The application of this classifier to the TCGA dataset identified 164 MES 
samples, 64 PN samples, and 24 PRO samples (A list of samples and their 
classifications is enclosed in the appendix [APPEND01]). These samples 
exhibited robust expression of the appropriate panel markers to the exclusion of 
panel markers of the other two subtypes, and clustering the TCGA samples by 
these subtypes correctly reproduced three distinct expression clusters that 
concurred with the Phillips et al panels, as shown below (red indicates increased 




After classifying the TCGA cohort into subtypes as defined by Phillips et al, hierarchical clustering of the patients 
according to the original classifying panel, when separate by subtype, reveals robust clustering of lineage-specific 
markers to the exclusion of markers of the other classes, as originally reported by Phillips et al.  
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When these samples were then checked for reciprocation of the reported 
separation of prognosis, I found a strong, statistically significant separation of the 
MES and PRO subtypes compared to the PN samples, as originally reported by 
Phillips et al. The p-value associated with the separation of Kaplan-Meier curves 
for the MES and PN samples was 2.99e-4. It should be noted that the TCGA 
dataset does NOT contain data from patients who survived cancer; all patient 
samples in the set have a time of death, which accounts for the discrepancies 
between the KM curves for the PN patients between the Phillips and TCGA 
datasets. 
 
   
 
Gene set enrichment analysis also confirmed that genes in the regulon of our 
predicted MES master regulators were significantly and specifically upregulated 
in TCGA samples classified as MES using this centroid-based classifier, leading 
us to conclude that I had accurately recapitulated the Phillips classification in the 
TCGA dataset. I used this classification scheme for the TCGA dataset as the 
basis for all subsequent analytic work. 
When separated into Phillips subtypes using a nearest-neighbor centroid classifier, TCGA tumor samples 
reciprocate the stratification of patient prognoses reported by Phillips et al: MES being indicative of the poorest 
prognosis, PN being indicative of the best. NOTE: the TCGA patient cohort does NOT include patients that 





Processing CNV and Gene Expression Arrays 
While Affymetrix SNP arrays are commonly used as a proxy to infer copy number 
alterations, our analysis of the data showed several technical issues that reduced 
their usefulness in searching for functional genomic mutations. Agilent CGH  
(comparative genomic hybridization) arrays are specifically designed to detect 
copy number alterations at gene loci, and they bear oligos that hybridize along 
the coding region of their target genes, as well as probes interspersed throughout 
non-coding regions. This ensures, at minimum, cover of genic regions in the 
genome. The Affymetrix SNP array is not designed with coding information in 
mind, a priori. SNP arrays contain panels of SNPs that have been identified as 
informative to the LD of underlying populations and are scattered throughout the 
genome. The implication of this, and the first issue, is that there are regions in 
the genome with less or inadequate coverage to accurately infer smaller-scale 
CNVs.  
 
As an example, CGH arrays 
successfully identified a focal 
amplification of the CEBPD locus on 
chromosome 8 as highly predictive of 
MES differentiation, even though the 
genomic region surrounding the locus 
Affymetrix SNP arrays sparsely populate numerous gene-
coding regions, preventing the detection of significant 
associations to molecular phenotypes such as the MES 
signature without employing integrative metrics. Even 
using these metrics never generates signals as 
significantly correlated to both expression and subtype 
classification as CGH array segmentation data. 
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was largely devoid of evidence for CNVs. I knew this was likely to be true 
because we have biologically validated CEBPD as a master regulator of MES 
differentiation. Furthermore, amplifications of CEBPD as reported by CGH arrays 
significantly correlated with increased expression of the CEBPD transcript, and 
increased expression of  
the CEBPD regulon. However, when the same region was analyzed using the 
SNP arrays, I found that there were no SNPs in the region that fell directly in the 
coding or promoter regions of CEBPD as shown in the figure provided (red 
hashes indicate SNPs that called an amplification event).  
 
SNPs falling nearest the CEBPD locus 
generated erratic and statistically weak 
associations to the poor prognosis MES 
sample subtype (see peaks 1, 2, and 3). 
Integrating over the region using a sliding 
window did improve the association of the 
region spanning CEBPD to the poor 
prognosis subtype, but ultimately did not 
perform as well as segmentation data 
produced by CGH. I also observed that 
no individual SNP or integration at the 
CEBPD genomic locus was able to 
produce as significant a correlation with 
Segmentation mapping of SNPs in the CEBPD region of 
chromosome 8 reveals that no SNPs in the array existed within 
the coding frame of the CEBPD gene. Because of this lack of 
coverage, no direct call on the CNV status was available, and 
standard GISTIC measures called the region diploid. CGH 
arrays, conversely, identified a focal amplification of the locus. 
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CEBPD transcript as simply using CGH segmentation mapping data: rMAX|SNP 
= 0.148 compared to rMAX|CGH = 0.258 using a simple Spearman correlation. 
 
Additionally, a comparative analysis was 
performed between using Agilent CGH 
segmentation files and GISTIC-processed 
Affymetrix SNP arrays. GISTIC is a data 
pre-processing algorithm designed to 
construct “minimum common regions” of 
genomic alterations by integrating signals 
obtained from adjacent SNPs, similar to a 
sliding window integration algorithm. The 
first issue that occurred was the a 
significant loss of resolution in minimum 
deleted/amplified regions due to a 
combination of the sparseness of SNPs, 
their non-uniform distribution in the 
genome, and GISTIC’s tendency to favor the joining of two mutated fragments 
over keeping separate segments. Shown here is an image of the segmentation 
mapping of the oft-deleted chromosome arm 9.p. This genomic locus bears the 
most common oncogenic suppressor that is deleted in GBM: p16. This 
chromosome arm typically suffers significant deletions and tumors are frequently 
found with this entire arm missing. However, CGH segmentation mapping of the 
Segmentation mapping of CGH probes to genes on 
chr9.p show significant evidence for independent 
deletion frequencies of genes across the TCGA 
sample cohort. GISTIC-processed SNP arrays assign 
this entire region as deleted in all of the included 
patients. Blue hashes denote significant evidence of 
deletion (Dark blue: homozygous deletion, Light blue: 
heterozygous deletion). Greyed area indicates the 
minimum region marked as deleted when applying 
the most lenient GISTIC thresholds. 
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area across a sampling of TCGA patients reveals significant evidence of 
irregular, partial, and nonequivalent alterations specifically of the p16 region, 
including significant probe-based evidence of differential copy number counts 
among genes in the region (while p16 is almost uniformly lost, the probability of 
losing other genes in a patient decreases as the genomic distance from p16 
increases). GISTIC mapping and SNP arrays call the regions equivalent; all are 
called as completely deleted for the entire region, which obscured a candidate 
identified by both the algorithm and MINDy: KLHL9.  
 
For these reasons, I opted to primarily use data obtained on Agilent CGH arrays 
for the CNV portion of the integrative analysis. Furthermore, I chose not to 
employ least common region mapping methods and post-processing such as 
GISTIC. These methodologies, while useful for inferring and mapping large-scale 
genomic alterations, tend to artificially bias against smaller, focal genomic 
changes since the integrations across focal regions will dilute out a true, small 
signal of change with large amounts of true signal of diploid status. This was also 
observed in, but not limited to, the focal amplification of CEBPD: individual 
segmentation mapping of the locus reveals significant evidence for an 
amplification when considering the probes that hybridize directly to the CEBPD 
coding region, but no other gene loci in the area show any evidence for 
alterations in an overwhelming majority of the patients assayed. 
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These analyses produced several results. I successfully established the ideal 
platform and formatting for the genomic CNV data. The CGH arrays provided by 
Agilent platforms proved to have better coverage of coding regions throughout 
the genome, and could most accurately reconstruct locus-specific CNVs without 
the reliance of sliding window integration algorithms such as GISTIC, which tend 
to compromise resolution of the CNV topography in highly-mutated areas and 
bias against the identification of focal genomic changes. Additionally, I have 
shown that the Phillips GBM subtype signatures are robust and extendable to 
independent datasets. In independent datasets, I was able to reproduce the 
subtype classifications using a centroid-based classifier that was trained on the 
Phillips cohort, and this classification successfully and robustly reproduced the 
association of poor patient prognosis to the MES subtype in the TCGA dataset. 
With this data in hand, I moved forward in using the TCGA dataset to identify 










CHAPTER 3 – DIGGIn, Part 1: Developing an algorithm to predict Drivers 
























Independently of the TCGA subtype classifications and CGH array 
standardizations, I developed an approach to infer causal mutations in GBM 
using the TCGA patient set. The approach required an algorithm capable of 
integrating genomic and gene expression data to assign what we coined 
“Functional” CNVs, which are then integrated with ARACNe and master regulator 
analysis results to produce candidate drivers of a molecular phenotype of 
interest. The general workflow is presented below, where the functional genetic-
genomic analysis occurs naïvely and independently to molecular classifications 
and ARACNe/master regulator analysis and then used in tandem with these data 
to arrive at a consensus for candidates.  Since the ARACNe, master regulator, 
and classification analyses are done independently and methodologies already 
exist to characterize the master regulators and downstream components, I 
focused on development of the DIGGIn algorithm: a pipeline to identify 
“functional” CNVs with the intent of making mesenchymal Drivers Inference from 
Genetic-Genomic Interactions. 
 
As a first step, I sought to develop an approach to pare down the likely candidate 
mutations. CGH array data covers the entire genome, including >20,000 known 
genes and associated regulatory regions; we hypothesized that very few of these 
genes would actually contribute meaningfully to the differentiation of the 
mesenchymal subtype, and testing for all loci would significantly reduce statistical 
power simply by including a majority of these irrelevant loci. Since GBM is a 
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disease primarily defined by chromosomal alterations (compared to point 
mutations), I sought to assign functionality to a genomic alteration by correlating 
it with a change in the transcriptional expression of genes that fell within the 
altered region in a fashion similar to a QTL. I hypothesized that a genomic 
alteration at a gene locus that functionally alters the transcriptional behavior of 
that gene should result in a correlation between the genomic event and 
transcriptional expression across the patient samples. This assumption also 
allows us to firmly attribute a causal direction to the perturbations and 
subsequent transcriptional cascade. An example is provided in the figure below: 
amplifications of the EGFR locus are biologically validated oncogenic drivers that 
are observed in a significant fraction of GBM patients. Concomitantly, patients 
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that bear evidence for EGFR amplifications in tumors also show greater 
transcriptional expression levels of EGFR. The mutation at this locus was the 
type of mutation I wished to uniquely identify.  
 
A natural extension of this methodology is to then infer the indirect molecular 
perturbations associated with a genomic mutation. After establishing that a 
genomic copy number change at a gene locus correlates with a change in 
transcription of that gene, the expression of all other genes expressed in the 
tissue can be tested for association with the genomic mutation. Effectively, this 
approach generates a transcriptional dysregulation network associated with each 
genomic mutation in the same vein as an ARACNe transcriptional network. 
However, I do not apply the Data Processing Inequality because the direct effect 
is already known (the transcription of the gene bearing the alteration), and 
indirect effects are the most informative in establishing how a genomic mutation 
propagates through the molecular network and affects the expression of specific 
gene sets. Through this workflow, I aimed to be able to infer candidate driver 
mutations from genomic mutations that can be predicted to alter the molecular 
behavior of a GBM tumor.  
 
Algorithm Workflow 
DIGGIn is designed to import two matrix files: one corresponding to gene 
expression data across a cohort of patients, and another corresponding to the 
genomic CNV segmentation data of the same cohort. The program is coded to 
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accept matrices that have gene / coding loci as matrix rows, and individual 
samples as the columns. Capitalizing on the computational simplicity of Mutual 
Information (discussed below) the program has been designed to dynamically 
match data between these two matrices using multi-dimensional associative 
arrays. Data is dynamically called from both matrices by their given sample and 
gene IDs, meaning that neither the row orders nor the column orders in the two 
matrices matters, so long as the labels used are the same between the two 
matrices. 
 
From these two files, DIGGIn follows several steps in order to predict functional 
genomic alterations. The details of each step are discussed in the subsequent 
sections. 
 
DIGGIn Phase I: Genetic-genomics analysis 
1. Find optimized kernel for Mutual Information estimation 
2. Build Mutual Information Null Distribution and compute p-value function 
3. Identify functional CNVs 
4. Link differential expression of other genes to functional CNVs (regulons) 
 
While the core of the genetic-genomic analysis identifies the predicted functional 
CNVs that should be considered for further analysis, the assigning of particular f-
CNVs as candidate drivers of any particular phenotype must be done in 
additional analytic steps. 
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DIGGIn Phase 2: Identifying candidate drivers 
5. Identify f-CNV regulons enriched in a gene panel of interest 
6. Identify increased activities in ARACNe-predicted master regulators 
7. Eliminate passenger mutations and identify maximum effect size mutations 
 
The integration with ARACNe and MINDy predictions, as well as statistical tests 
for association to molecular, clinical, and phenotypic outputs occurs at a post-
processing level, which is discussed in chapter 4. A full schematic of the DIGGIn 
architecture is provided below, detailing the inputs and outputs to each of the two 
phases of DIGGIn, and how they integrate with other systems biological methods 
such as ARACNe and MINDy. Solid lines indicate DIGGIn-specific flow that was 
developed specifically in this thesis. Broken lines indicate established 
methodologies such as ARACNe/MINDy and generalized identification of 





















The DIGGIn algorithm can be broken into two general phases. Phase I integrates genomic profiling and gene 
expression data to identify a set of CNVs that exist in genes with a concomitant change in gene expression. The 
expression of all other genes in the genome are then compared to these “functional” CNVs to assign indirect 
dysregulation. Phase II of DIGGIn interrogates these functional CNVs for statistical enrichment of gene marker 
panels and/or enriched activation of master regulators and modulators provided by ARACNe/MINDy. Phase II also 
implements several conditional association metrics to identify combinations of mutations for the maximum effect 
size across the available sample space. DIGGIn-specific flow is outlined with solid arrows. Previously available 
methodologies and how they relate to the DIGGIn framework are outlined in broken arrows. 
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Mutual Information  
I opted to measure the dependence of differential gene expression on genomic 
mutation using the information theoretic metric, Mutual Information. This is the 
central metric used by the ARACNe algorithm and it has been shown in several 
models to detect biologically-validated transcriptional interactions between 
transcription factors and their targets to a degree that is missed by more 
traditional statistical tests. Mutual information is a probabilistic measure capable 
of detecting non-monotonic correlations between continuous variables, and has 
several advantages over more traditional statistical methods. It does not require 
arbitrary discretization of data, it has low computational complexity, and does not 
require a priori information or inferences on the distribution or topology of the 
data used. The first point was a particularly important consideration given the use 
of CGH arrays for detecting copy number variants. Traditional copy number 
analysis involves assigning a statistical threshold to reject the null hypothesis, 
locus count = 2. Using these types of methods in an integrative analysis would 
require a statistically dependent discretization of the CGH data, followed by 
another statistically dependent measure of co-information, introducing multiple 
additional hypothesis corrections and results that are highly dependent on the 
original thresholds set. Instead, mutual information allowed us to consider the 
entire range of CGH array values as a vector of continuous random variables and 
tie them to patient-matched expression vectors. 
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Mutual information between a matched pair of continuous random variables, x 
and y, is defined as: 
! 













wherein p(x) and p(y) are the marginal probability functions for random variables 
in sets X and Y, and p(x,y) is the observed joint probability density function of the 
matched variables.  
 
The mutual information function measures statistical depdence as the ratio of the 
observed probability of two variables co-occurring, p(x,y) to the expected 
probability given statistical independence, p(x)*p(y), weighted by the expected 
probability of p(x,y). If X and Y were conditionally independent (the outcomes of 
X never affect Y and vice versa) then the predicted probability of the two 
variables co-occurring is equal to the product of each event occurring separately, 
p(x,y) = p(x)*p(y). In this instance, the function simplifies to log(1) = 0 information, 
and it can be claimed that they are mutually independent or that no information 
exists between the variables (again, x does not affect y; therefore knowing x tells 
nothing about y). If the events are not mutually independent, p(x,y) > p(x)*p(y), 
and the function produces a non-zero value, providing a quantitative value of the 




For the purposes of inferring interactions between gene expression or between 
genomic-genetic pairings in a rank-sorted dataset, we measure the probability 
density functions for the log ratio using a kernel bandwidth estimator that weights 
neighboring datapoints based on their distance from each tested point (discussed 
below). However, the expected probability of any individual pairing of variables 
(or each individual point), p(x,y), is equal to 1/M, where M is the number of 
samples in the probability space. Thus, the definition of mutual information in our 
context can be reduced to: 
 
 
wherein the remaining term corresponding to the observed p(x,y) is inferred by a 
probability density function created from the sets X and Y. In the case of genetic-
genomics, the X vector would represent a vector of continuous variables 
corresponding to the copy number status of a tested genomic locus, indexed by 
sample. Conversely, the Y vector would represent patient-matched expression 
values of genes being tested for co-information with the mutation status at locus 
in vector X. 
 
Mutual information across continuous random variables can be efficiently 
estimated using a Gaussian kernel estimator to construct non-Normal probability 
density functions for variable sets X and Y, defined: 
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Fitting a Gaussian kernel with an optimized bandwidth estimator, h, as a window 
for measuring variance allows for efficient estimation of MI between variables, 




While such an estimator is asymptotically unbiased in infinite or large datasets, in 
finite datasets a bias does exist and depends on the kernel width used. Since 
kernel selection is largely heuristic and empirical, this can lead to MI estimates 
whose accuracy varies, based on kernel selection. However, the performance of 
MI in this context is not directly dependent upon the fidelity of the MI estimate to 
the true MI value, but instead depends on the accuracy of MI rank estimates. 
Statistical significance is established by testing MIxy ! MI0, where MI0 is defined 
as the mutual information threshold obtained from the null distribution at a given 
significance[8][9]. In this context, the bias attributable to kernel selection is 
minimized, so long as a kernel that is optimally fitted for the dataset being 
analyzed is held constant across all comparisons and the modeled null 
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distribution. The end results are MI values whose ranks are directly comparable 
to those produced in the null distribution to ascertain a p-value.  
 
As reported by Margolin et al., selecting a variety of kernel bandwidth values did 
not significantly alter the results of the analysis for a majority of the mutated loci, 
as long as the same kernel estimator was used in both the construction of the 
null distribution and the analytics, allowing h optimization to be a largely heuristic 
process. The most significant changes in results involved loci whose mutational 
frequency was low (<5% of patients tested exhibited 
evidence for a locus alteration) and the gene 
expression vector had a low coefficient of variation. 
The ramifications and solutions to this are 
discussed below. Therefore, rather than optimizing 
a kernel for every M2 number of comparisons (an 
extremely resource-intensive process), I instead 
optimize a single kernel width by selecting for the 
kernel value that minimizes the MI between random 
vectors. I take a Monte Carlo model approach and 
compute over 105 iterations the MI from randomly 
paired CNV and gene expression vectors under 
different kernel widths starting from h = 0.9 to 
h=0.01 and select the maximum value h wherein the 90th percentile of the 
recorded pairs falls below MI=0.05. This kernel width is then used for all 
The null distribution for estimating MI 
p-values is made by measuring the 
MI between randomized CNV and 
gene expression vectors over 10e5 
iterations and measuring the 
frequency of each MI value. The 
exponential decay of the function in 
the right tail allows a linear fit to log-
transformed data for the extrapolation 
of arbitrarily small p-values 
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subsequent analysis and the null distribution generated is then used for the 
calculation and extrapolation of p-values, and for all subsequent analytic 
measurements of MI in the dataset. This approach ensures the selection of a 
maximum value h such that the (MI | h) in the null distribution allows for 
maximum dynamic range in detecting non-random co-information between tested 
CNV and gene expression vectors.  
 
The null distribution corresponding to the optimal kernel, h, is used to estimate MI 
to arbitrarily small p-values. 105 randomized iterations allows for the construction 
of a probability density function from which I can assign a p-value, p, to any 
recorded MI value. This distribution is asymptotically distributed on the right tail, 
which allows us to log-transform the empirically determined p-values and fit a 
linear function to the data. From this fit, I can estimate arbitrarily low p-values 
without having to run large numbers of iterations in the MI null distribution. For 
the work with TCGA GBM, the critical MI value for rejecting H0 was set as the MI0 
with an FDR < 0.1. based on 105 iterations. 
 
Results and Analysis 
Following the standardization of the TCGA data, I performed the analysis to infer 
functional genetic mutations. Of the ~9,000 genes expressed in the patient 
samples and full ~20,000 gene loci tested for genomic alterations, only 1489 
genes had alterations that shared significant mutual information with their gene 
expression (a list of these genes is included in its entirety in [APPEND02]). 
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These alterations were subsequently flagged as functional CNV genes (f-
CNVGs), genes whose genomic loci showed evidence of an alteration that 
correlated with a change in transcription levels of the same gene. Any f-CNVG 
could subsequently be considered a candidate causal driver mutation, since the 
genomic event could be definitively linked to a molecular perturbation. Testing 
the performance quality of DIGGIn included two basic tests: reciprocation of 
known ARACNe transcriptional regulons when those TFs were mutated, and the 
successful identification of bona fide oncogenic drivers previously reported in 
GBM.  
 
Successful recapitulation of Transcriptional Regulons 
Among the 1489 identified f-CNVGs were several transcription factors including 
the validated mesenchymal master regulator, CEBPD. I compared the panel of 
genes that showed statistically significant MI with the mutated transcription 
factors against the ARACNe-predicted targets of each transcription factor in GBM 
and the mesenchymal signature as a whole. As expected, there was statistically 
significant overlap between the differential expression panel predicted by the f-
CNVG analysis and the predicted transcriptional regulon: the overlap of 
ARACNe-predicted targets of CEBPD and the genetic-genomic predicted targets 
of CEBPD was highly enriched (p<6.58e-17). The enrichment of mesenchymal 
signature genes associated with the deletion of KLHL9 was also highly significant 
(p<2.00e-9). DIGGIn was able to properly associate the dysregulation of known 





Successful identification of gold standard Oncogenic Drivers 
As an additional quality control metric, I tested whether DIGGIn was capable of 
identifying common mutations that have already been reported in the literature. 
DIGGin was successfully able to identify several classical oncogenic drivers as f-
CNVGs. Of the 18 classical oncogenic drivers reported[21] as GBM oncogenic 
drivers, the algorithm positively identified 14, including loci such as EGFR, CDK4, 
MYCN, p16, PTEN, RB1, and NF1, for a statistically significant enrichment of 
true-positive mutations (p<1.93e-10). The remaining four were either too rare in 
the TCGA population tested to obtain statistical significance (all candidates 
missed with significant mRNA calls were present in <10 TCGA samples, <5% of 
the set) or were disregarded as potential drivers because the transcript was not 
found in the tissues, implying that changes in expression were not possible and 
were therefore non-perturbing. This latter point was one of the initial goals in 
designing the algorithm; the omission of artificial candidates via the integration of 
additional biological information drastically improved the computational power in 
parsing the data into meaningful mutations. These findings showed that the 
algorithm was able to attribute changes in gene expression levels of oncogenic 
drivers to the mutations that occurred at their genomic loci (a list of these genes 
is provided in [APPEND03]). Based on these results, I concluded that any 
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candidates successfully identified by the algorithm could be expected to be a 
legitimately functional CNV to be included in subsequent analysis. 
 
 
Detection of rare, yet functional mutations via the MINDy algorithm 
One caveat of the use of mutual information is the relatively large data 
requirement to obtain usable MI estimates. It was established that roughly 100 
independent samples was the absolute minimum required for ARACNe to have 
sufficient statistical power to produce robust transcriptional networks[1][8]. While 
the TCGA dataset included over 200 patients, there was an added constraining 
limitation on the power: a non-uniform distribution of mutations across the 
patients. Certain loci, such as EGFR and p16, were altered in over 60% of the 
patients and showed a very dynamic range of gene expression, providing ample 
information across “affected” and “unaffected” patients to generate co-information 
with gene expression. In contrast, copy number changes that were more rare or 
whose gene expression had lower coefficients of variation provided less 
information. Though I did not bin or discretize the data, using continuous 
variables when a rarer mutation is being tested results in highly-clustered points 
in a joint probability density function, diluting the ability to detect information over 
the null distribution without a specifically-optimized kernel. Although it may 
appear conceptually ideal to favor mutations with the highest effect size when 
considering candidate driver mutations, there is always the possibility of a very 
important, yet rare, contributor to the etiology of a highly heterogeneous disease.  
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To address this issue, we also implemented the MINDy (Modulator Inference by 
Network Dynamics) algorithm[2][22][23] to detect and identify a priori candidate 
modulators of the MES master regulators. Implementation of the genetic-
genomic algorithm on the TCGA GBM dataset showed that, while the algorithm 
was highly successful at parsing functional mutations when the mutations were 
present in relatively large portions of the population, it had difficulty detecting 
functional CNVs when they existed in fewer than ~5% of patients overall (<10 
patients) if the variance of gene expression or CNV reads was relatively high. 
The MINDy algorithm provided a complementary approach wherein potential 
modulators of the MES master regulators were predicted a priori from the gene 
expression profiles. These candidates were then cross-referenced with CNV data 
to ascertain whether any patients carried mutations in gene loci of the MINDy-
predicted modulators. This approach does not require any minimum number of 
affected patients, but simultaneously does not provide statistical evidence that 
can be used to predict effect size. However, including the MINDy modulators 
significantly expanded our coverage of reported oncogenic drivers. 
 
For comparison, DIGGIn was modified to use statistics to measure correlation 
between CNVs and gene expression. Both the Mann-Whitney U-test and 
Student’s T-test were used to measure a change in gene expression between 
samples that were binned into “diploid,” “amplified,” or “deleted” groups. This 
methodology requires assigning two statistical thresholds: one to assign 
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significant evidence for copy number change, and another to ascertain significant 
differential expression between samples with vs. without copy number change.  
 
While these approaches were able to reasonably detect functional CNVs at a 
population threshold lower than MI, these approaches did not outperform a 
simple cross-comparison of CNVs at gene loci and MINDy-predicted modulator 
loci, due largely to the dependency on multiple statistical thresholds with 
corrections for multiple hypothesis testing. Related to this, the cross-comparison 
method is a much more intuitive approach, requiring significantly less pre-
processing and fewer variable thresholds. The results of the parametric analyses 
could significantly change based on the thresholds used for differential 
expression, copy number alteration, and minimum effect size considered. Since 
MINDy successfully identified nearly every rare locus that was detected in the 
traditional methods, I opted to use MINDy.  
 
In summary, the DIGGIn algorithm was designed to implement mutual 
information to identify what I refer to as f-CNVs. f-CNVs are genomic copy 
number variations occurring at gene loci that present with a concomitant 
alteration in the transcriptional expression of the genes contained in that CNV. 
This allows for a powerful filtering step to remove a significant amount of probes 
(and therefore hypotheses) to be tested when identifying candidate mutations for 
further study. However, additional processing is required to assign specific f-
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CNVs as driver mutations for specific molecular expression panels like the MES 























CHAPTER 4 – DIGGIn, Part 2: MES-specific candidate drivers are identified 























Interrogation for MES Gene Expression and Master Regulator Activity 
The initial steps of DIGGIn are designed to identify functional CNVs. These 
genomic mutations are the mutations that can directly be associated with a 
molecular perturbation of the genes expressed in a tumor. In order to do so, I 
adapted the mutual information function derived for the ARACNe algorithm and 
applied it to the integration of genomic and gene expression array data. Phase I 
of DIGGIn defines genomic loci that have a traceable link between a mutation of 
a gene and differential expression of that gene. It also defines all the genes 
whose expression is affected indirectly by this gene locus. These significant 
functional CNVs, or f-CNVs are defined as a subset of candidate driver loci, 
isolated from a field of hundreds of thousands of candidate loci. 
 
However, CNVs do not fall exactly within single genes at a time. They occupy 
variably large swaths of genomic regions and can manipulate any combination of 
genes expressed in the tumor, which can regulate any number of independent 
biological processes. In order to specifically identify candidate drivers of 
mesenchymal differentiation, I needed to create an algorithm with additional 
metrics to assign likely function to this specific molecular profile. Phase II of 
DIGGIn is a suite of analyses integrating conditional associations, and modeled 
off of classical genetic testing in order to rank and select candidate f-CNVGs that 
are maximally likely to drive the phenotype of interest. 
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I ascertained whether any of these 1500 f-CNVGs could specifically regulate the 
genes in the mesenchymal gene expression panel by conducting an enrichment 
analysis on the f-CNVG’s “regulon,” comprised of all other genes whose mRNA 
expression shared significant information with the genomic perturbation. f-CNVG 
loci were flagged as potential MES differentiation drivers if their regulons were 
statistically enriched in genes in the MES gene expression panel defined by 
Phillips et al. This was subsequently cross-referenced with the results of the 
MINDy algorithm as applied to the TCGA GBM cohort to obtain consensus 
candidates (genes identified by both methods) and potential candidates (genes 
identified by at least one method). This enrichment analysis was conducted using 
the standard GSEA protocol with an FDR < 0.1. The genes that carried 
statistically significant enrichment of differentially expressed MES marker genes 
are included in [APPEND03]. Of the ~1500 f-CNVG loci successfully identified, 
only 41 were significantly enriched specifically in genes that define the MES gene 
expression signature, and identified by both genetic-genomic approaches and 
MINDy as a potential driver, including amplifications in the previously identified 
master regulator, CEBPD. Two genomic loci presented high enrichment in both 
the activation of the MGES and increased activity of all predicted MES master 






The above figure displays two types analyses that 
DIGGIn is capable of conducting on defined f-
CNVs. In the event that an ARACNe network is not 
available, a more straightforward approach can be 
conducted by testing each f-CNV for increased 
activity of a biomarker panel of interest as a whole, 
pitted against the total size of the f-CNV’s 
dysregulatory hub. This is represented in the figure 
by the blue squares. Alternatively, ARACNe master 
regulators can be integrated into DIGGIn and we 
can instead measure master regulator activity. We 
define activity of a transcription factor in this context 
as the collective change in expression of its 
ARACNe-predicted targets. By measuring the 
coordinated change of a TF’s targets, we have a 
proxy for the TF protein’s activity (more active TFs 
will produce more target transcripts). Using this 
measure, DIGGIn can infer which f-CNVs are predicted to contribute to the 
increased activity of specific master regulators, such as the mesenchymal master 
regulators indicated as yellow squares. This analysis is conducted independently 
of the standard statistical enrichment, but generally produces better results when 
f-CNV hubs become large. 
Of the 41 genomic CNVs that 
had significant MI with MES 
master regulators, the two loci 
with the most significant 
enrichment of both the MES 
signature genes and, 
subsequently, the activity of the 
ARACNe-predicted master 
regulators (yellow squares) 
were amplifications of CEBPD 
and deletions of KLHL9. Master 
regulator activity was measured 
as a function of the differential 
expression of the MR’s 
ARACNe-predicted targets. 
While simple enrichment by 
Fisher’s Exact test of MGES 
genes was significant for these 
two loci, testing for master 
regulator activity provided more 




Selecting MES Driver Candidates 
The functional CNVs at CEBPD and KLHL9 were significantly enriched in MES 
genes and MES master regulator activity, and were subsequently considered 
potential driver mutations that could induce mesenchymal differentiation in GBM 
tumors among the 41 candidates. However, there are still two issues that had to 
be addressed before positively stating that KLHL9 and CEBPD were mutated 
master regulators/modulators of MES transformation in GBM: 
  
1) There are an unknown number of causal driver mutations amidst 
hundreds, if not thousands, of mutated loci.  
 
2) CNVs tend to affect large genomic regions; whole chromosomal deletions 
are affected in GBM, which means that any mutated locus that drives the 
differentiation a subtype will usually come with several other neighboring 
loci that are also associated with the subtype, but are biologically 
irrelevant. 
 
To address the first issue, I implemented a recursive greedy search algorithm 




X0 = argmax(m • s)
while(pFET (Xi) < "){
mi = {m \ Xi#1}
si = {s \ Xi#1}




The TCGA GBM cohort was classified into MES, PN, and PRO subtypes 
according to the classifier trained from the Phillips work. A vector set, s, was 
defined containing each sample classified as MES or PN. A complementary 
vector set, m, was defined containing the mutation state of each candidate 
genomic locus across all patients in s. A candidate driver f-CNV, X0, was 
selected by finding the maximum the dot product between the candidate f-CNV’s 
vectors m and s. X0 was essentially tested for association specifically to the MES 
subtype compared to the PN subtype and a p-value could be assigned by a 
Fisher’s Exact Test (FET). X0 is subsequently the first candidate driver identified 
and accounts for some portion of samples in the vectors m and s. 
 
Subsequently, the vectors m and s are updated to contain only the set of 
samples that existed in the original vectors that are NOT also contained in the set 
of samples that bear the mutation X0. Using the new sets m1 and s1, the next 
most significant locus associated to the mesenchymal subtype is identified, X1. 
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This analysis is recursively repeated until statistical significance of association 
can no longer be achieved with the remaining samples in each vector. 
 
The use of the argmax function with the Fisher’s Exact Test in a greedy search 
indirectly pushes the algorithm towards selecting candidate f-CNVs that offer the 
maximum effect size detectable by statistical methods, which manifests in the 
selection of two types of candidates. The value to this approach is that it is 
capable of detecting significant associations resulting of both high-frequency 
mutations (more prevalent mutations will provide more statistical power, 
reflecting higher effect size) and rarer but highly specific mutations (mutations 
may be more rare but only occur in specific sets of samples, producing high 
associations) as long as the distribution of mutations are approximately equal.  
 
However, due to the unequal distributions of mutations throughout samples, 
there is a significant risk of the analysis favoring very common mutations (>50% 
of the samples) to the exclusion of very rare ones (<5% of samples) simply due 
to the difference in power associated with limited sample sets; stronger p-values 
are more readily obtainable when the mutation is more prevalent, such that a 
significant driver mutation that occurs in only 5% of samples may be 
overshadowed and placed in a superset with a more common mutation simply 
because the minimum p-value obtainable in this context is an order of magnitude 
higher than other candidates. This can lead to false positive where multiple, 
independent true driver mutations are placed in the superset of another, non-
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causal mutation simply because this mutation is so common that it co-occurs with 
multiple drivers.  
 
To hedge against this occurrence, each subgroup of TCGA patients associated 
to a significant candidate f-CNV was redefined as the entire MES cohort, and the 
recursive analysis was repeated to ensure that there were no viable 
subcategories of sample sets as defined by individual candidate drivers.  
 
As a result of this analysis, we were surprised to find that ~50% of the MES 
samples could be accounted for by bearing a mutation in only one of two loci: 
amplifications of CEBPD (one of the biologically validated master regulators of 
the MGES), and deletions of KLHL9, a previously unreported gene in tight 
linkage disequilibrium with one of the most prevalent mutations in GBM, deletions 
of p16. 
 
To parse out false positives resulting from being in linkage disequilibrium with a 
true driver mutation, I devised a computational algorithm based on the following 
hypothesis: Of all mutations that are statistically associated with each other (co-
occurring), no mutation can be more significantly associated with the MES 
phenotype than a true driver MES differentiation.  
 
This can expressed mathematically by comparing the association of two 
hypothetical associated genes, genex and geney, to the MES subtype compared 
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to the PN subtype. A mutation (mut) at genex can be correctly identified as a 
candidate driver if, when all other co-mutated genes y in superset Y are wildtype 




This indicates that any co-information between geney and the MES subtype is 
actually an artifact of information passed to it from genex by statistical 
association. Conversely, any gene for which this does not hold true can be 
identified as a passenger mutation since its association to the mesenchymal 
subtype is conditionally dependent upon the mutation at another locus. If the 
mutation frequencies are such that there are no samples that are mutated at 




I constructed associative networks of co-occurring mutations by performing a 
pair-wise Fisher’s Exact test matching all ~1500 f-CNV genes with each other. 
From this map, I extracted all genes that were statistically associated with 
amplifications of CEBPD and deletions of KLHL9. Any of these loci could be a 
true driver of the MES subtype instead of KLHL9 or CEBPD, due to their high co-








(PN;genexWT | geneymut ) < pFET (PN;geneyWT | genexmut )
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conditional association of each locus to the MES classification across TCGA 
samples, given that another co-mutated gene was not mutated. If the conditioned 
locus is the true driver, the association of the tested locus should be abrogated 
(no condition, or gene in this case, can be more associated to the effect than the 
cause).  
 
This analysis concurred that the most likely driver genes were CEBPD and 
KLHL9, as conditioning on the absence of these two mutations completely 
removed the association of any other genomic loci that were co-mutated with 
them. Conversely, the associations of KLHL9 and CEBPD to the MES subtype 
were the most robust to conditioning on the absence of other mutations. 
 
In order to identify and biologically validate mesenchymal drivers in this GBM 
patient cohort, a series of experiments were designed to assign both statistical 
association of candidate drivers to the MES subtype and associated poor 
prognosis, and biological validation of the molecular function of these mutations 








CHAPTER 5 – Deletion of the KLHL9 E3 Ligase Complex Adaptor Protein 

















DIGGIn was designed to identify candidate genomic mutations that drive the 
activation of distinct molecular expression panels. This is accomplished using a 
two-step analytic process where functional genomic mutations are identified, then 
subsequently interrogated for statistical enrichment of the gene panels of interest 
(in this case, mesenchymal differentiation). The results of the DIGGIn analysis on 
the TCGA cohort identified KLHL9 as a previously unreported candidate driver of 
mesenchymal differentiation in GBM. I followed up this candidate driver with a 
series of statistical analyses on independent human cohorts and biological 
experimentation in cell lines. The full process of implementation of DIGGIn and 
subsequent analysis are detailed in this manuscript. 
This manuscript is currently undergoing revisions for resubmission to Nature and 
contains the implementation of DIGGIn as described in this thesis. It additionally 
details the biological methods and experiments used to validate the identified 
candidate, KLHL9, and the subsequent identification of the mechanism by which 
it interacts with the validated mesenchymal master regulators, CEBPB and 
CEBPD. All figures and figure legends for this manuscript have been attached to 
appendices 5 and 6 ( [APPEND05] and [APPEND06]). Additional experiments 
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The most aggressive subtype of human high-grade glioma (HGG) is characterized 
by expression of mesenchymal genes (the “mesenchymal signature”), a 
phenotype driven by aberrant activation of master regulators C/EBP! , C/EBP"  and 
STAT31. Yet, the specific genetic alterations contributing to this tumor subtype 
remain largely unknown, despite availability of large-scale mutational and gene 
copy number alteration datasets2. We hypothesized that the master regulators of 
the mesenchymal subtype represent a natural bottleneck, responsible for 
canalizing aberrant upstream signals from multiple genetic alterations. Confirming 
this, unbiased genome-wide regulatory-network analysis of these genes and of 
their upstream regulators identified focal amplifications of C/EBP! and frequent 
deletions of KLHL9, an adaptor of Cullin3-based E3 ligases, in poorest prognosis 
mesenchymal HGG tumors. Loss of KLHL9 in tumors leads to C/EBP" and 
C/EBP! protein accumulation, while re-expression of the gene triggered ubiquitin-
mediated, proteasome-dependent destruction of these transcription factors, 
abrogated the expression of mesenchymal genes, and promoted cell cycle arrest. 
An independent HGG patient cohort confirmed KLHL9 deletion in 70% of poor 
prognosis cases. Taken together, these data elucidate a previously unidentified 
KLHL9 deletion as the most frequent alteration promoting aggressive 
mesenchymal subtype of HGG and provide a novel, regulatory-network based 





High-Grade Glioma (HGG), including astrocytoma grade III and IV, are the most 
common human brain tumors and are virtually incurable, with an average survival 
of 12 months post diagnosis3. Gene expression profiling of HGG samples from 
large patient cohorts, using a gene subset that optimally correlates with disease 
prognosis, has revealed three subtype-specific signatures, including 
mesenchymal (MGES), proliferative (PGES), and pro-neural (PNGES) markers 
respectively4. Among these, the MGES was found to be associated with the 
worst prognosis, as further confirmed by analysis of additional Glioma datasets1, 
including TCGA5 and Rembrandt6. More recently, co-segregation analysis with 
large-scale gene copy number (GCN) alteration and mutational data5 revealed an 
alternative signature stratification, including Proneural, Neural, Classic, and 
Mesenchymal7, with the Mesenchymal expression signature again associated 
with the worst disease prognosis. This allows us to use the Mesenchymal gene 
expression signature is a quantitative molecular proxy for poor prognosis GBM. 
 
Analysis of the mesenchymal signature, using a regulatory network inferred de 
novo by the ARACNe algorithm, elucidated three Master Regulator (MR) genes – 
the transcription factors (TFs) C/EBP!, C/EBP", and STAT3 – as synergistic 
drivers of the mesenchymal gene expression signature of high-grade 
glioma1_ENREF_3. The C/EBP! and C/EBP" subunits form both homo- and 
heterodimers that regulate the same targets. Co-ectopic expression of C/EBP! 
and STAT3, but not of either gene in isolation, was sufficient to reprogram neural 
stem cells along an aberrant mesenchymal lineage. Conversely, co-silencing of 
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the two genes abrogated the mesenchymal phenotype in short-term cultures of 
human HGG-initiating cells and established glioma cell lines, both in vitro and in 
vivo. Finally, stratification of an independent cohort using C/EBP! and phospho-
STAT3 antibodies revealed that functional co-activation of these TFs was 
associated with the worst prognosis in ~70% of the patients.  
 
Among the relatively large panel of genetic alterations reported by the TCGA 
Consortium5, only NF1 mutations were statistically associated with the MGES, 
accounting however for < 25% of the worst prognosis samples, thus leaving the 
majority of genetic variance associated with worst prognosis unaccounted for. 
Despite the growing availability of data and the identification of clinically relevant 
molecular subtypes within HGG, the genetic alterations contributing to this 
subtype remain virtually unknown and none has been mechanistically elucidated.  
 
Here we introduce and experimentally validate the “bottleneck hypothesis,” i.e. 
the concept that master regulators of a tumor subtype implement functional 
bottlenecks that canalize and integrate aberrant upstream signals from a 
spectrum of driver genetic alterations, thus constituting a central dependency of 
the phenotype (oncogene or non-oncogene addiction8). Specifically, if the co-
activation of C/EBP and STAT3 is both necessary and sufficient to establish an 
MGES subtype, then relevant genetic alterations must be harbored either by the 
master regulators themselves or by their upstream functional regulators. 
Integration of copy number alteration data and regulatory network analysis 
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upstream of these MR genes confirmed this hypothesis, leading to the 
identification and functional validation of the focal amplification of the C/EBP" 
locus and deletion of the KLHL9 locus, which account for the majority of 
mesenchymal and worst prognosis samples in glioblastoma (GBM). Additionally, 
this analysis suggests a possible functional role for NF1 as an upstream post-
translational regulator of STAT3. Indeed, its inactivation by deletion and mutation 
co-segregates with C/EBP" amplifications, consistent with the established 
mechanism of synergistic mesenchymal signature activation in GBM, which 




Identifying Functional Copy Number Variations 
To reduce the number of candidate copy number variations (CNV) that may play 
a functional role in dysregulating MRs of the MGES signature, thereby regulating 
a major molecular program associated with poor prognosis in GBM, we defined 
functional CNV Genes (f-CNVGs) as genes within CNV loci whose copy number 
was informative of their expression level by either mutual information analysis or 
t-test statistics, see methods section. The analysis was performed using a set of 
229 TCGA samples for which both gene expression and copy number profiles 
were available from Affymetrix (HU-133) and Agilent (CGH) respectively, with no 
subtype selection. Only genes passing these criteria were subsequently 




The analysis identified 1486 f-CNVGs at a p-value p < 0.05 (Bonferroni 
corrected); see Figure 1b. f-CNVGs that frequently co-occur in the same samples 
were grouped into 34 clusters, based on sample co-segregation analysis, see 
methods. As expected, cluster membership was mostly determined by genomic 
proximity, since f-CNVGs at distant loci were relatively independent of each 
other, except for cases where large fragment of a chromosome were recurrently 
deleted or amplified. For instance, f-CNVGs on chromosome 9, which is 
frequently deleted in GBM, were clustered together. However, they were 
statistically independent of f-CNVGs on chromosome 12 (Figure 1a).  
 
Based on this metric, the vast majority of CNVs did not appear to affect 
expression of their corresponding genes (see for instance Supplemental Figure 
2a). We thus tested whether this filtering may be too conservative by checking for 
the successful identification of established oncogenic drivers as f-CNVGs. The 
vast majority of established GBM genetic alterations were preserved by the 
analysis, including 14/18 gene copy number alterations previously identified as 
classical GBM tumorigenesis drivers5, such as EGFR, CDK4, PDGFRA, MDM2, 
MDM4, MET, AKT3, MYCN, PIK3CA, CDKN2A, CDKN2C, RB1, PTEN, and NF1, 
see Supplemental Figure 10. The remaining four genes were not identified as f-
CNVGs due either to insufficient analytical power, because the corresponding 
CNV frequencies were too low for statistical association with the corresponding 
gene expression, or because there was no evidence of differential expression 
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due to the CNV. For example, the CDKN2B locus was omitted as a candidate f-
CNVG, despite a high frequency of deletion and linkage to CDKN2A because 
CDKN2B expression was not detected in these GBM samples. Previous studies 
that lack this selection step would consider this locus as a candidate gene based 
on the genomic array data, despite the fact that the expression array data 
precludes it from functionally altering the molecular behavior of these tumors. 
Supplemental Figure 2b, for instance, shows the strong association between the 
CNV harboring the EGFR gene and its mRNA expression. Additionally, among 
previously identified MGES MR genes (C/EBP!/", STAT3, FOSL2, BHLHB2, and 
RUNX1), only C/EBP" was identified as an f-CNVG by this analysis, based on 
coordinated amplification and overexpression in ~22% of the samples; see 
Figure 1. This suggests that aberrant functional activation of C/EBP and STAT3 
most frequently arise from upstream genetic or epigenetic events rather than 
from direct amplification events. 
 
Identification of f-CNVGs as candidate modulators of MGES  
To identify f-CNVGs that may drive the aberrant activity of MGES MR genes, we 
applied two complementary approaches to the TCGA data. First the MINDy 
algorithm9 was used as a genetic-genetic approach to identify all upstream 
candidate functional modulators of the transcriptional activity of C/EBP!, 
C/EBP", and STAT3. Inferred modulators that were also detected as f-CNVGs or 
that harbored mutations reported in 5 were then selected for further analysis. 
Succinctly, MINDy tests whether the expression of a candidate modulator M may 
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affect the strength of the regulatory relationship between a TF and its targets ti. 
This is accomplished by computing the conditional mutual information 
! 
I = [TF;ti |M] between TF and target, given the modulator availability. MINDy 
was successful in the identification of both known and novel modulators of MYC 
in human B cells, which were experimentally validated9, and in the analysis of 
interactions between all signaling proteins and TFs also in human B cells10.  
 
Concurrently, we used a genetic-genomic approach, inspired by 11, to find 
f-CNVGs whose presence in specific samples would be associated with master 
regulator activity, measured as a function of MES marker expression. This was 
accomplished by computing the mutual information between each f-CNVG and 
the of the established MGES MR genes, including C/EBP!, C/EBP", STAT3, 
FOSL2, BHLHB2, and RUNX1. MR activity in each sample was inferred from the 
expression of their ARACNe-inferred transcriptional targets1, see methods 
section.  The combination of these two analysis identified 184 of the original 1486 
f-CNVGs as candidate modulators of MGES MR genes by either analysis, and 41 
of those 184 were identified by both methods (see Supplementary Table 8). 
These 1486 f-CNVGs were then clustered into co-mutated groups via simple 
pairwise statistical association methods, revealing that the majority of these 
mutations fell into linked regions on various chromosomes (Figure 1a). 
 




The 184 f-CNVGs emerging from the previous analysis were then tested for 
actual association with the MGES molecular subtype. The subtype classification 
was established using a signature-based sample classification, as described in 
1_ENREF_3, see methods section. Specifically, samples were classified as either 
MGES or non-MGES, and the association of samples bearing mutations at each 
f-CNVG to each of the subtypes was assayed. Consistent with MR analysis, all 
but two of these f-CNVGs displayed statistically significant enrichment of the 
expression MGES marker genes.  
 
These loci were further tested to identify the loci with the greatest effect size 
associated with the mesenchymal tumors. A recursive analysis was performed to 
determine the smallest subset of the f-CNVGs that was both maximally 
associated with the MES subtype, and accounted for the maximum number of 
MES tumor samples; see the methods section, Testing for CNV association by 
recursion, for details.  
 
Two f-CNVGs emerged as having both high effect size and statistically 
significance to the MGES subtype by genomic and molecular genetic 
association. These include the single-gene focal amplifications of the C/EBP" 
locus on chromosome 8, in 31 of 144 (22%) MGES samples vs. 1 of 51 non-
MGES (p ! 2.1E-5), and the deletion of the KLHL9 locus on chromosome 9, in 55 
of 144 (38%) MGES samples vs. 3 of 51 non-MGES (p ! 8.14e-7). Of the 144 
MGES samples, 17 (12%) presented genetic alterations at both loci (synopsis in 
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Figure 1b). Overall, this resulted in highly differential distributions, with significant 
independent p-values for C/EBP"amp/KLHL9WT (p ! 9.9E-3) and KLHL9-
/C/EBP"WT (p ). Overall, 69 of 144 MGES samples (48%) presented at least one 
of the two genetic alterations vs. only 4 of 51 non-MGES samples (p ! 1.15e-9). 
This result was based on a highly conservative threshold, normally used for 
genome-wide CNV inference, suggesting that these alterations may be even 
more frequent. 
 
One additional test was implemented to ensure that KLHL9 and C/EBP" were 
the most likely drivers among the mutations that they co-occur with in patients. In 
particular, KLHL9 is located in a frequently deleted chromosomal region that 
includes CDKN2A (p16), one of the most frequently deleted tumor suppressors in 
GBM. It is thus legitimate to ask whether the identification of KLHL9 as an 
association with the MGES subtype may be an artifact due to its proximity to 
CDKN2A. To address this issue, all mutations that statistically tended to co-occur 
with these two mutations in patients (obtained from Figure 1a, shown in Figure 
2a) were tested for association to the MES subtype given the absence of another 
co-occurring gene. This procedure is explained in greater detail in the Methods 
section: Testing for candidate f-CNVGs among co-mutated clusters. Figures 2b 
and 2c synopse the results of the analysis. This analysis revealed that, of all the 
tested f-CNVGs, only those for C/EBP" and KLHL9 could abrogate the MGES 
association of every other cluster f-CNVGs, while still showing significant 
conditional association across virtually all tests. Indeed, no other f-CNVG was 
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statistically significant after conditioning the analysis on these two alterations. 
These results suggested that the two genetic alterations were the most likely 
causal ones among those considered in the analysis. We conclude from this that 
the mutations of KLHL9 and C/EBP" are in fact the most likely drivers of the 
MES phenotype based on a consensus of genetic, genomic, and associative 
analysis. 
 
This analysis was also conducted on genes selected by chromosomal proximity 
to the C/EBP" and KLHL9 loci. Supplementary Figure 8 shows that statistical 
association of the KLHL9 deletion to the MGES subtype is substantially 
increased when only CDKN2A deleted samples are considered (Supplementary 
Figure 8b, blue line), while the statistical association of CDKN2A deletions with 
the MGES subtype is completely abrogated when conditioned on the absence of 
KLHL9 deletions (Supplementary Figure 8b, red line). This suggests that KLHL9 
deletions rather than CDKN2A deletions account for the association of this 
genomic region with the MGES.  
 
Interestingly, deletions and mutations of the NF1 gene were also associated with 
MGES samples. However, these events tended to co-occur with C/EBP" 
amplification and were not statistically significant following conditional association 
analysis. Since NF1 was inferred by MINDy as a STAT3 modulator and since 
activation of both C/EBP and STAT3 is necessary for reprogramming along the 
mesenchymal lineage, this suggests that these two events may cooperate, i.e. 
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that MGES samples harboring the C/EBP" amplification may also harbor STAT3 
activating alterations, including NF1 deletions and mutations7.  
 
Using a stringent threshold for their identification, C/EBP"+ and KLHL9- 
alterations account for 48% of the MGES samples in the TCGA dataset, with 
deletions/mutations at the NF1 locus covering an additional 8% independently of 
C/EBP" amplifications or KLHL9 deletions7, suggesting that these may constitute 
the most common alterations associated with the MGES subtype of GBM, 
especially since many mutated samples may be missed duet to the conservative 
threshold selection to minimize false positives.  
 
Alterations of C/EBP" and KLHL9 predict poor prognosis independently of 
molecular classification 
Since alterations of C/EBP" and KLHL9 were both associated to and predicted to 
regulate the mesenchymal signature, the molecular predictor of poor prognosis 
GBM, we tested whether or not these mutations are sufficient to predict poor 
prognosis. We obtained an independent set of genomic DNA from 63 primary 
GBM tumor samples provided by Ken Aldape and assayed them for deletions of 
KLHL9. We used Kaplan-Meier statistics on the original TCGA dataset to test 
whether alterations in C/EBP" and KLHL9 were also good predictors of poor 
patient prognosis, independently of prior molecular classification, as originally 
observed. The Kaplan-Meier survival curve of samples with mutations in either of 
these loci differed significantly from the survival curve of “good” prognosis GBM 
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patients (Figure 3a, p ! 3.46e-4). Additionally it was statistically significantly 
distinct from a cohort of all samples that are diploid at these two loci, regardless 
of molecular- or prognosis-based classification (Figure 3a, p ! 0.0319).  
 
The C/EBP" gene codes for one of the master regulators that induce direct 
activation of MGES genes1. Thus the mechanistic relevance of its amplification in 
mesenchymal samples is obvious. Conversely, the mechanism by which deletion 
of KLHL9 drives expression of mesenchymal genes in glioma is unknown. Thus, 
we set out to determine the functional significance of KLHL9 deletions for 
mesenchymal transformation of HGG. 
 
KLHL9 deletions are enriched in an independent cohort of poor prognosis 
patients and predict elevated CEBP protein levels 
We asked whether KLHL9 deletions might be frequently found in an independent 
cohort of poor-prognosis glioma samples, compared to good prognosis ones. We 
analyzed the status of the KLHL9 genomic locus by quantitative genomic PCR 
(qgPCR) from a set of 63 formalin-fixed, paraffin-embedded (FFPE) primary 
glioma samples collected at the MD Anderson Cancer Center from two separate 
cohorts. These included 10 poor-prognosis (<35 weeks survival) and 9 good-
prognosis (>130 weeks survival) samples. The other primary samples were 
samples obtained from the TCGA that were not part of our original analytical set, 
also classified into good and poor prognosis. qgPCR analysis revealed a 
significantly higher frequency of KLHL9 homozygous deletions in poor-
  
77 
samples (21/40) compared to good prognosis samples (4/23) (Figure 3a, b), 
resulting in a very significant p-value (p < 5.6e-3 by FET), see Figure 3b. This 
suggests that KLHL9 may be frequently deleted (>50%) in poor prognosis 
samples, above the frequency determined by a stringent cutoff in TCGA CNV 
data analysis (38%). Genomic DNA sequencing of the samples lacking deletion 
of KLHL9 failed to reveal the presence of mutations in the coding sequence of 
KLHL9. 
 
Concurrently, we performed IHC assays to check the protein levels of the master 
regulators CEBP" and C/EBP#. We observed that, as shown before, MES GBM 
tumors are characterized by unique expression of these two proteins. We were 
subsequently able to show that KLHL9 deletions strongly predict the presence of 
mesenchymal levels of CEBP" and C/EBP# (odds ratio 12.25, p=0.0283) on a 
cohort of 20 primary samples tested, shown in Figure 3d. 
 
Re-expression of KLHL9 in KLHL9-/-; CDKN2A-/- human glioma depletes C/EBP! 
and C/EBP" proteins. 
To assess whether KLHL9 deletions activate the function of the previously 
validated MRs of the MGES subtype (C/EBP!, C/EBP", and STAT3), we asked 
whether restoring the expression of KLHL9 in cells carrying homozygous deletion 
of the endogenous KLHL9 gene may affect expression of their mRNAs and/or 
proteins. From the genomic analysis of KLHL9, CDKN2A, C/EBP" and EGFR 
genes in eight human glioma cell lines we found that the SF210 cell line harbors 
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homozygous deletion of both KLHL9 and CDKN2A whereas all the glioma cell 
lines were diploid at the C/EBP" locus (Supplemental Figure 4). Thus, the SF210 
line provides an ideal cellular system to investigate the functional consequences 
of KLHL9 restoration in KLHL9 and CDKN2A double-deleted glioma. 
 
We used a lentiviral vector to transduce SF210 with a doxycycline inducible full-
length KLHL9 gene. We selected two SF210 stable clones showing (DOX)-
induced expression of KLHL9 mRNA 48 hours after induction this effect was 
sustained for at least 96 hours (Figures 4a). Consistently, KLHL9 protein levels 
were stably detected by western blot, up to 96 hours post induction (Figure 4c). 
An inducible GFP clone was also validated and used as a control in all 
subsequent experiments. 
 
RNAseq experiments on these cells revealed that 48 hours of restored KLHL9 
expression coincided with a significant shift in expression of CEBP-predicted 
transcriptional targets (Figure 4b) compared to GFP mock transfected cells. 
Furthermore, the mesenchymal marker genes predicted to be regulated by either 
CEBP shifted to suppressed expression, despite no significant changes in the 
expression levels of either C/EBP! and C/EBP" (inset 4b), including genes such 
as YKL40 and FN1.  
 
While their mRNA levels remained unchanged, KLHL9 expression coincided with 
markedly decreased protein levels of master regulators C/EBP! and C/EBP" but 
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not of STAT3 (Figure 4c). Additionally, ectopic KLHL9 expression triggered 
similar down-regulation of the positive control AuroraB protein, which is known to 
be destabilized and degraded by a KLHL9-containing, cullin3-based E3 ubiquitin 
ligase complex12,13. No equivalent protein changes were detected when the GFP 
control SF210 cells were treated with DOX. Taken together, these results 
indicate that re-expression of KLHL9 induces the suppression of MGES marker 
genes via the loss of the two MGES master regulators C/EBP! and C/EBP" at 
the protein level. 
 
Furthermore, the suppression of C/EBP!/" protein levels was observed in a 
CDKN2A null background, thus confirming that CDKN2A deletion in isolation is 
not sufficient to maintain high protein expression of the master regulators. This 
suggests that deletion of KLHL9 is sufficient to activate the two previously 
validated master regulators of the MGES, thus significantly contributing to the 
induction of mesenchymal transformation in GBM, independently of CDKN2A 
expression. 
 
KLHL9 promotes poly-ubiquitylation and proteasomal-mediated degradation of 
C/EBP! and C/EBP"  
Given that KLHL9 is an adaptor of cullin 3-based E3 ligases13, and the 
observation that C/EBP!/" proteins decrease without change in their mRNA 
levels following KLHL9 expression, we tested whether ectopic expression of 
KLHL9 in glioma cells may trigger ubiquitylation-dependent, proteasome-
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mediated degradation of C/EBP TFs. To test this hypothesis, we measured the 
half-life of C/EBP! and C/EBP" proteins in the presence or absence of KLHL9 in 
SF210 cells treated with the proteasome inhibitor MG-132 versus controls. The 
proteins’ half-life was measured while protein synthesis had been abrogated by 
the translational inhibitor cyclohexamide (CHX). These experiments revealed that 
the half-life of C/EBP!/" was markedly reduced from >4 hours in control SF210 
cells, lacking KLHL9 (GFP-expressing clones in the presence of DOX and 
KLHL9-inducible clones in the absence of DOX), to  ~1-2 hours in the SF210 
cells in which KLHL9 had been restored by treatment with DOX. Inhibition of the 
proteasome by MG-132 restored accumulation of the C/EBP proteins in the 
presence of KLHL9 (Figure 5a). The results indicate that re-expression of KLHL9 
in glioma cells triggers proteasome-mediated degradation of the C/EBP TFs. 
Furthermore, an interaction was detected between the CEBP proteins and the 
KLHL9 protein, as assayed by a co-immunoprecipitation using KLHL9 to pull 
down the CEBPs (Figure 5b). 
 
To test whether proteasome-mediated degradation of C/EBP!/" proteins by 
KLHL9 was also ubiquitylation-dependent, we prepared cell lysates in the 
presence of MG-132, with and without KLHL9 expression, and tested for 
ubiquitylation of immunoprecipitated C/EBP! and C/EBP" by western blot. 
Following expression of KLHL9 and proteasomal inhibition, poly-ubiquitylated 
C/EBP! and C/EBP" were significantly increased in comparison to uninduced 
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controls, see Figure 5c, thus confirming that KLHL9 promotes both poly-
ubiquitylation and proteasome-dependent degradation of C/EBP TFs.  
 
Rescuing with a mutant KLHL9 protein suppresses ubiquitylation of CEBPs 
Finally we cloned a KLHL9 protein bearing a 70 aa deletion in the N-terminal end 
of the protein corresponding to the cullin-interacting BTB domain of the protein 
(Figure 6a). This domain is responsible for bringing the ligase/target complex to 
the cullin scaffold, which also brings in an E2 adaptor bearing ubiquitin, 
mediating the transfer of the ubiquitin to the target. Upon exogenous rescue with 
this mutant construct, we successfully abrogated both the detection of 
ubiquitylated CEBP species upon immunoprecipitation (Figure 6b) to levels that 
match a GFP-transfected, KLHL9 null molecular behavior, as well as the 
suppression of CEBP proteins 48 hours post expression (Figure 6c).  
 
KLHL9 expression suppresses the proliferation of glioma cells 
Expression of C/EBP TFs and presentation of a mesenchymal phenotype are 
hallmarks of aggressiveness in HGG. We thus assayed the effects of KLHL9 
expression on cellular growth over 96 hours in the DOX-dependent, KLHL9-
expressing SF210 clones.  
 
Immunofluorescence microscopy, following KLHL9 induction, revealed the 
emergence of large, extensively spread cells with enlarged nuclei that failed to 
incorporate EdU (red signal), compared to uninduced controls (Figure 7a), 
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suggesting that KLHL9 expression may suppress mesenchymal glioma cell 
proliferation. These large cells appeared only upon induction of KLHL9 and 
accounted for 38% of the cell population. Less than 5% of these large cells had 
any detectable EdU signal, compared to 70% incorporation frequency observed 
in the GFP control cells. To further quantify this effect, we measured BrdU 
incorporation via flow cytometry. Cells expressing KLHL9 for 48 hours (Figure 7b, 
red series) showed a significant reduction in BrdU incorporation relative to 
uninduced controls (Figure 7b, black series) following a 24-hour BrdU pulse, 
based on integrations of the area under the BrdU-positive and -negative peaks. 
To corroborate this observation, we also measured cell growth by normalized cell 
counts of DOX-induced clones versus DOX induced GFP clones and uninduced 
controls over a 96-hour timecourse. DOX treatment of GFP controls did not 
significantly alter the growth of the cells, whereas expression of KLHL9 
correlated with a significant decrease in cell growth that was detectable at 72 
hours post-induction, and was maintained through at least 96 hours (Figure 7c). 
 
DISCUSSION 
Analysis of large CNV and mutation datasets is providing an extraordinary 
window over the genetic events that underlie tumorigenesis and tumor 
progression. Unfortunately, the number of genetic alterations that are statistically 
associated with most solid tumors tends to be very high, due also to recurrent 
large-scale genomic rearrangements. As a result, an increasing challenge of 
cancer research is to be able to separate driver mutations from passenger ones. 
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Equally importantly, extensive knowledge on established oncogenes and tumor 
suppressors usually hampers elucidation of genes located in their chromosomal 
proximity as viable candidate driver mutations. For instance, even though we 
showed that KLHL9 is frequently mutated in the MGES subtype of glioblastoma, 
its proximity to CDKN2A prevented it (as well as many other genes in that region) 
from being previously considered as independent contributions to the subtype 
etiology.  
 
In contrast, regulatory network based analysis established KLHL9 as an ideal 
candidate for functional validation, independent of its proximity to CDKN2A, 
because of its computationally inferred role as a strong modulator of MGES MR 
activity. Not only could we elucidate the specific mechanism by which KLHL9 
modulates turnover of C/EBP TFs, by poly-ubiquitylation dependent proteasomal 
degradation, but analysis of an independent cohort of poor versus good 
prognosis GBM patients revealed this gene as even more frequently deleted than 
originally suspected from TCGA data analysis (>70% versus 38%). This suggests 
that current thresholds for mutational analysis may be over-conservative, likely to 
minimize false positives detection in genome-wide studies, and that more 
realistic threshold could be used if the number of candidate genes could be 
reduced via regulatory network based approaches, as shown in this study.  
 
Recently, integration of regulatory network based approaches with GWAS data 
has been successful in identifying a handful of phenotype-relevant genetic 
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alterations14. However, this analysis has always proceeded in a genome wide 
fashion, thus requiring highly conservative thresholds for evaluation of statistical 
significance.  In this manuscript, we presented and validated the “bottleneck 
hypothesis,” i.e., that some cancers are characterized by functional bottlenecks, 
implemented by master regulator TFs, which integrate aberrant signals 
originating from a spectrum of genetic and epigenetic alterations in their 
upstream regulators. Under such assumption, analysis of genetic alterations in 
the master regulators and in their upstream regulators can elucidate key genetic 
alterations that would have otherwise been missed.  Interestingly, master 
regulator bottlenecks may fail to harbor genetic alterations, making their 
identification difficult by conventional mutational analysis approaches. For 
instance, using gene candidate approaches, we have previously elucidated Nf-$B 
as a master integrator of aberrant events in its upstream pathways within the 
ABC subtype of Diffuse Large B Cell Lymphoma even though it is never itself 
mutated15. Similarly, of the three MGES master regulators in GBM, only C/EBP" 
was significantly amplified. Thus, despite their critical functional role, none of 
these key genes could have been identified by traditional mutational or copy 
number variation analysis.  
 
A first corollary of the bottleneck hypothesis is that regulatory network based 
analysis of genes that are upstream functional regulators or modulators of master 
regulators of a tumor subtype may be much more effective in providing 
candidates driver mutations than unconstrained GWAS. Importantly, as shown, 
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the collapse in the number of candidate mutations made possible by regulatory 
network analysis allows efficient use conditional association methods to separate 
driver from passenger mutations. This approach would be completely implausible 
if it had to be performed on all mutations that are statistically associated with a 
phenotype of interest.  
 
A second corollary of the bottleneck hypothesis, especially when combined with 
the results of 1, is that individual genetic events, such as C/EBP" amplifications 
or KLHL9 deletions, may be too rare or unlikely to provide appropriate targets for 
pharmacological intervention. Conversely, by integrating an entire spectrum of 
aberrant signals from upstream genetic alterations, functional bottlenecks 
implemented by master regulators may constitute more universal biomarkers and 
pharmacological targets (i.e., universal oncogene or non-oncogene addition 
points of the cancer subtype) because of their ability to integrate the effect of 
many low-frequency mutations.  
 
A final corollary is that the bottleneck hypothesis may help identify key genetic 
alterations that are either not focal or are harbored by genes located in close 
chromosomal proximity to well-established oncogenes and tumor suppressors. In 
the past, the approach has been to simply ignore such genes to reduce false 
positives. Yet, there is no functional reason why genes within large, frequently 
deleted or amplified regions or in close proximity to established oncogenes 
should be less likely to be drivers of the phenotype. Indeed, regulatory network 
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based analysis was successful in identifying the role of KLHL9 deletions, which 
are both non-focal and in close proximity to CDKN2A, one of the most frequently 
deleted genes in GBM. 
 
KLHL9 deletions in HGG result in mesenchymal transformation because of 
aberrant stabilization of the master regulator C\EBP TFs. At least two other 
genes coding for E3 ubiquitin ligases undergo loss-of-function genetic alterations 
in HGG. The first gene codes for Fbw7, an F-box protein of the SCF complex that 
is mutated in several forms of human cancer including HGG16. Fbw7 mutations 
stabilize the oncoprotein substrates cyclin E, Myc and Notch17. The second gene 
coding for an E3 ligase, which can be deleted in HGG, is Huwe1, a Hect-domain 
ubiquitin ligase that normally triggers initiation of differentiation and loss of self-
renewal in the developing brain by targeting the N-Myc oncoprotein for ubiquitin-
mediated degradation by the proteasome18. Our findings indicate that loss-of-
function events targeting E3 ubiquitin ligases in human cancer not only promote 
aberrant stabilization of classical oncoproteins thus contributing to cancer 
development but they can also trigger accumulation of key TFs responsible for 
specific tumor signatures and aggressive phenotypes.  
 
Clearly, the ability to identify both cancer bottlenecks and their candidate 
upstream functional regulators depends critically on the availability of accurate 
and comprehensive repertoires of cell-context specific molecular interactions 
(interactomes). While the assembly of integrated transcriptional, post-
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transcriptional, and post-translational interactomes is still in its infancy, the 
genome-wide integration of experimental and computational approaches appears 
to be providing increasingly descriptive and biologically relevant models, 
suggesting that network based biology may be an increasingly valuable tool in 
our repertoire of approaches to elucidate the mechanism of key physiological and 
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TCGA data processing 
Somatic copy number variation (Agilent) and gene expression data for 229 TCGA 
tumor samples were downloaded from the TCGA Data Portal. Clinical data for a 
subset of these patients was also acquired from the Data Portal. The gene 
expression arrays were GCRMA-normalized, and the copy number variation log 
ratios were extracted from the CNV array data.  
 
Agilent CGH arrays were used instead of the also available Affymetrix SNP array 
data because probe coverage of key loci was sparse in the latter; For instance, 
the C/EBP" locus had no probes within the coding region of the gene, and 
associations that were detected in the CGH arrays were not detectable in the 
Affymetrix data without using more sophisticated, sliding-window integration 
methods across probes in the region (Supplemental Figure 5). Additionally, 
overall stronger CNV – gene-expression dependencies were detected using the 
Agilent CGH array data. For instance, Affymetrix probes proximal to the C/EBP" 
locus showed no correlation with C/EBP" expression, without sliding window 
integration, and were overall less correlated than those reported by CGH arrays 
(Supplemental Figure 6). 
 
Inference of Functional CNV Genes (f-CNVG) 
f-CNVGs were identified by integrating gene expression and copy number 




IF = I[CNVi;mRNAi] To allow identification of low-frequency genetic alterations, 
genes lacking significant MI between their CNV and their expression were also 
tested for differential expression conditional on copy number changes, using a by 
T-test for all alterations with >1 prevalence and a Z-test for single-occurrence 
mutations. 
 
The dependency between CNV at a locus x and a gene y at the same locus was 
measured based on the pair-wise mutual information between the vector of gene 
expression values of y across all samples, and the vector of CNV log ratios of x 
across the same samples: MI[x;y]="x"ylog(p(xy) / p(x)p(y)), using a Gaussian 
kernel estimator. Values of MI[x;y] that were statistically significant at a p-value 
p < 0.05, Bonferroni corrected for the total number of tested pairs, were used to 
identify candidate f-CNVGs. The statistical threshold for MI significance was 
determined from a null distribution built by computing the MI between 10,000 
randomly paired CNV and gene expression vectors (Supplemental Figure 3). 
 
This approach offers two advantages. First, it can detect statistical dependencies 
originating from non-linear relationships between the two vectors that may be 
missed by other measures of statistical independence, such as Pearson 
correlation. It also removes the need for three independent statistical significance 
tests per gene: one to detect significant gene differential expression, one to 
detect a significant CNV, and one to assess significant correlation between the 






All f-CNVGs identified by the previous test were then clustered based on same-
sample co-segregation. This was done using Fisher’s Exact Test on the number 
of overlapping samples presenting the alteration, at a p < 0.05 statistical 
significance threshold, Bonferroni corrected for the number of multiple tests. All f-
CNVG pairs that showed significant correlation are connected by an edge in 
Figure 1b. Clusters of co-mutated f-CNVGs were identified by higher association 
scores between genes in the cluster than between those genes and genes 
outside of the cluster; genes that had a much higher probability of being co-
mutated clustered together when using the association p-value as a metric. 
 
For each inferred cluster of co-segregating f-CNVGs, we computed the mutual 
information between the corresponding f-CNVGs and the activity of each of the 
mesenchymal master regulators, C/EBP!/", STAT3, FOSL2, BHLHB2, and 
RUNX1 originally identified as MRs of the MGES signature. The mutual 
information was computed and tested as discussed for the CNV – gene-
expression case, using testing for statistical enrichment of each MR’s targets, as 
identified from the ARACNe-inferred transcriptional networks19,20 rather than 





Network-Based Association Study: Testing for f-CNVG association by recursion 
Following classification of the TCGA GBM tumors into poor- and good-prognosis, 
the candidate mutations identified previously enriched in differential expression of 
the MES genes were tested for association to the MGES and poor-prognosis 
phenotype recursively. Across all available samples, each f-CNVG was tested for 
association to the MES subtype. The f-CNVG with the highest association across 
all comparisons was identified, and all patient samples bearing that f-CNVG were 
removed from the dataset. This association analysis was then repeated to 
identify the next highest-association f-CNVG until no additional significant 
associations could be identified.  
 
Network-Based Association Study: Testing for candidate f-CNVGs among co-
mutated clusters 
 
Once a candidate f-CNVG for the MES subtype was identified, it was subjected 
to an additional analysis to account for the possibility that its association is an 
artifact of another mutation that co-occurs with it in patients. In order to test this 
an analysis was designed under the following hypothesis: among all co-mutated 
genes, only the true, causal mutation will remain associated to the molecular 
subtype across various genetic backgrounds. Therefore, all of the mutations that 
were found to statistically co-occur with a candidate driver (obtained from the 
association map in Figure 1A) were conditionally tested for association to the 
MES subtype, given that another gene in the co-mutated cluster was not 
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mutated. This pair-wise analysis was performed for every pairing of genes in the 
co-mutated cluster, searching for a mutation that, when removed from the 
background, caused the association of all other genes in the cluster to become 
insignificant. 
 
Classification of TCGA GBM tumors 
TCGA tumor samples were reclassified into poor-prognosis and good-prognosis 
phenotypes based on the activity of master regulators originally reported as 
drivers of the most aggressive subtypes of GBM: the C/EBP!/", STAT3, FOSL2, 
BHLHB2, and RUNX1 (Supplemental Figure 1a). Molecular classification by the 
activity of these genes via a centroid-based, nearest-neighbor classifier produced 
two groups separable by prognosis at a statistically significant level 
(Supplemental Figure 1b), and served as the basis for subsequent associative 
analyses. Clustering TCGA tumor samples by prognosis and testing for 
differential activity of both MGES master regulators and signature genes 
recapitulates the finding that these genes are accurate predictors of poor 
prognosis. See figure 1b). 
 
Genomic KLHL9 copy number characterization in an independent HGG cohort  
Genomic DNA was extracted from ten poor-prognosis (post-diagnosis survival 
<35 weeks) and nine better-prognosis (>135 weeks) paraffin-embedded HGG 
obtained from the MD Anderson Cancer Center and tested for copy number 
changes of relevant genes by quantitative genomic qPCR. The copy-number 
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status of the KLHL9 gene was analyzed by quantitative amplification of two 200-
bp amplicons, at the 5’ and 3’ ends of the KLHL9 coding sequence respectively, 
according to the methods discussed in the qRT-PCR Methods section. The entire 
coding sequence of the KLHL9 locus was also sequenced to scan for possible 
mutations from samples that showed successful amplification. 
 
Plasmid constructs 
Bacterial cultures were grown on agar plates with appropriate selection at 28C. 
Transformations into DH5% cells (Invitrogen) were performed using the 
recommended protocol.  
 
The coding region of the KLHL9 locus was amplified from genomic DNA obtained 
from 293T cells using the following primers: KLHL9-BsshII-F (5’-
GGCAGCGCGCatgaaagtgcccttggtaacg-3’) and KLHL9-XhoI-R (5’-
GCGCTCGAGctaagaatgatctgaaggtgctga-3’) with the AccuPrime TAQ system 
(Invitrogen). This PCR product was digested with BssHII and XhoI and ligated 
into the pEN_TTmcs inducible expression vector with the Rapid DNA Ligation Kit 
(Roche) according to the kit’s protocol.  
 
After sequencing for mutations, the KLHL9 locus insert was introduced to the 
lentiviral packaging vector pSLIK via Gateway cloning (Invitrogen). A GFP-
pEN_TTmcs was also cloned to a pSLIK vector and included as a negative 




Cell lines/Cell culture 
SF210 and 239T-FT cells were grown in DMEM +10%Fetal Bovine Serum 
(Gibco,BRL), incubated at 37C with 5% CO2.  
 
Stable, inducible KLHL9 and GFP-SF210 cells were generated by transfecting 
the appropriate pSLIK vectors and supplementing plasmids into 239T-FT cells 
with JetPEI Transfection Reagent (Polypus Transfection). 24 hours post-
transfection, the virus-bearing medium was aspirated off, vacuum-filtered, and 
placed over pre-confluent SF210 cells. After 48 hours of infection, SF210 cells 
were placed under G418 selection at 1 mg/ml for 7 days.  
 
KLHL9-infected SF210 cells were then cloned via dilution limit to obtain 
monoclonal cell populations. GFP-control transfected cells were left as a 
polyclonal population. Cells were then checked for KLHL9 or GFP expression by 
induction with 2ug/ml doxycycline (Sigma) for 24 hours. GFP production in GFP 
controls was verified by fluorescent microscopy, and KLHL9 expression was 
verified by qRT-PCR at 24 hours, and Western Blotting at 72 hours. Isolated 








Total RNA was prepared from cells using the Cells-to-cDNA kit (Ambion), and 
reverse-transcribed to cDNA via first-strand cDNA synthesis using the qScript 
cDNA kit (Quanta Biosciences) according to manufacturer protocols. Real-time 
PCR was performed using SYBR Green PCR Master Mix (Applied Biosystems). 
DNA samples were run in biological triplicates and technical duplicates. 
Comparative fold changes were computed using the ##CT method normalized to 
internal controls of GAPDH expression. 
 
RNAseq experiments 
Total RNA from six samples (3 each of KLHL9-rescued and mock-rescued) were 
prepared via TriZOL precipitation and purified using Qiagen RNeasy columns. 
Samples were tested for integrity via Bioanalyzer and submitted to the Columbia 
Sequencing center. 
 
Differential analysis was performed using a t-test. These p-values were used as 
the ranking for a subsequent gene set enrichment analysis (GSEA) to ascertain 
whether specific biomarker sets were differentially expressed when KLHL9 was 
rescued or not. 
 
Western Blotting 
Cell lysates were prepared from SF210-KLHL9 and SF210-GFP cells after 72 
hours of either doxycycline treatment or control medium by lysing them in RIPA 
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buffer (Sigma Aldrich) with Complete MINI EDTA-free protease inhibitors 
(Roche). Lysates were quantified using the BCA Protein Assay (Pierce) following 
manufacturer protocol. 
 
The antibodies were used at 1:500 (KLHL9), 1:10,000 (B-actin), 1:1000 (C/EBP!, 
C/EBP", STAT3, Ubiquitin), 1:10,000 (AURKB, goat-anti-mouse), and 1:20,000 
(goat-anti-rabbit). Blocking and antibody incubations were done in SuperBlock 
T20 TBS Blocking Buffer (ThermoScientific). All antibodies were obtained from 
Santa Cruz. 
 
Protein half-life time courses 
KLHL9-4 (SF210 cells transfected with KLHL9) and GFP control (SF210 
transfected with GFP) cells were grown to pre-confluence in 10cm plates. Plates 
were then split into 6-well plates in DMEM-10%FBS with 2ug/ml doxycycline and 
left for 24 hours. 30 minutes prior to the start of cyclohexamide treatment, one 
KLHL9-4 series was treated with 10uM MG-132 while the others were treated 
with DMSO (the MG-132 solution used was dissolved in DMSO). After 30 
minutes, all cells were treated with a DMEM-10%FBS cocktail of doxycycline 
(2ug/ml) and cyclohexamide (20uM), and additionally with MG-132 (10uM) where 
appropriate. 
 
At the end of the time course, cells were washed with ice-cold PBS and scraped 
from the plates, and lysed in RIPA buffer with protease inhibitors. Lysates were 
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quantified using the BCA Protein Assay Kit (Thermo Scientific), and separated by 
SDS-PAGE and immunoblotted as previously described. 
 
Densiometric analysis was done using the ImageJ software suite. 
 
Immunoprecipitation 
Whole lysates were prepared in either RIPA buffer (ubiquitin IP experiments) or 
Cell Lysis Buffer from Cell Signaling (Co-IP) from KLHL9-induced and -
uninduced clones subjected to 24 hours of doxycycline (2ug/ml) treatment. IPs 
for ubiquitylated protein species were additionally treated with the proteasome 
inhibitor MG-132 for 4 hours after doxycycline treatment (10uM). C/EBP!/" 
proteins were immunoprecipitated using antibodies from Santa Cruz and the 
DynaBeads G Immunoprecipitation kit (Invitrogen) following manufacturer 
protocols. Eluted C/EBP!/" proteins were separated by SDS-PAGE and 
transferred to nitrocellulose membranes according to standard Western blotting 
protocols and probed for ubiquitin, and C/EBP!/" (Santa Cruz). 
 
Generating KLHL9 mutants  
The deletion of the BTB domain in KLHL9 was generated using PCR fusion. 
Primers were designed for the 5’ and 3’ so to generate a full length KLHL9. 
These primers were then paired with 50-bp primers that were designed to be 
homologous to the 25 base pairs immediately before and after the BTB domain. 
After amplifying two separate DNA products corresponding to the KLHL9 
  
99 
fragments before and after the BTB domain, bearing 25-bp homologous ends, 
these two products were combined into a third PCR amplification reaction with 
the original full-length product primers. This final PCR reaction fuses the two 
fragments together, producing in frame KLHL9 DNA without the BTB domain. 
 
This construct was then cloned into the expression vector pLCPX for 
transfection, alongside clones containing the wild type KLHL9 and the empty 
pLCPX parent vector for controls. 
 
Cell growth time courses 
For an initial time point, and each desired time point, a 6-well plate was prepared 
by seeding ~500 SF210-KLHL9 or SF210-GFP cells into the wells. Induced wells 
were plated with 100ul of DMEM 10% FBS and a final concentration of 2ug/ml 
doxycycline, while the remaining three received 100ul DMEM 10% FBS. Cell 
counts for seeding were determined using a Countess automated cell counter 
(Invitrogen). Cells were seeded in biological triplicates. 
 
At each time point, cell growth per well was quantified by counting the cells on 
the plate using the Countess cell counter. Growth curves were built by 
normalizing cell counts at each time point to the counts obtained from the 





BrdU Flow Cytometry 
SF210; KLHL9-4 clones were grown for 96 hours with or without induction via 
doxycycline according to the methods already provided. After 96 hours, BrdU 
(Calbiochem) was introduced to the cells at a 1:2000 concentration for 24 hours 
as instructed by manufacturer protocols. 
 
The following day the cells were fixed in BD Cytofix/Cytoperm reagent (BD 
Biosciences) and stained with fluorescent anti-BrdU (BD biosciences) according 
to the manufacturer’s protocols. These cells were then analyzed via flow 
cytometry (20,000 cells per treatment recorded) and analyzed with the FlowJo 
software suite. The upper/lower limit for left/right peak intervals was defined 
using the negative control distribution; all events exceeding the 99th percentile 
BrdU measure in the negative control distribution were considered BrdU-positive, 
and the remainder BrdU negative (demarcated by the dotted line). The integrals 
for these peaks were computed and displayed as [left peak : right peak] 
percentage ratios. 
 
EdU Immunofluorescent Microscopy 
Visualization of EdU incorporation was performed using the Click-It EdU HCS 
Assay Kit (Alexa 647) from Invitrogen. Cells were seeded at 500, 1000, 2000, 
and 4000 cells per well in a 96-well plate, in biological triplicates for each 
treatment (induced and uninduced). Cells were left to grow for 72 hours. After 72 
hours, all subsequently exposed to EdU at a 1:2000 concentration for 24 hours. 
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Cells were then fixed in 4% paraformaldehyde, and both staining and 
visualization were then carried out according to manufacturer protocols. 
 
Raw grayscale images generated by the microscopy analysis were then colored 
and composites were created using the ImageJ software suite. All image 
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During the review process for our manuscript, I continued to work on improving 
the biological validations of the KLHL9 master regulator. I received a fresh 
selection of huGBM cell lines from the University of California, San Francisco 
after they performed quality control experiments to ensure that the aliquots 
matched data generated when they were first isolated. Of the panel of five 
aliquots was one vial of low-passage SF210, and an additional cell line that was 
validated as bearing a homozygous co-deletion of KLHL9 and p16: SF763. 
Verification was conducted using the same genomic qPCR methods described 
previously, with results shown in [Figure 5a.1]. These validated aliquots were 
selected to allay issues that may arise from unknown maintenance and 
accumulated mutations that may 
have occurred in the original 
aliquots we received and worked 
with. The KLHL9 gene was 
additionally cloned into the 
lentiviral expression vector pLOC 
and validated by sequencing to 
provide an independent vector with 





Two validated cell lines obtained from UCSF were 
verified as bearing homozygous deletions for KLHL9 
and CDKN2a (p16): SF210 and SF763 
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These cells were subsequently amplified and used for repeat validation 
experiments in the rescue of KLHL9. Both cell lines reciprocated the reported 
increased protein turnover of the CEBPB and CEBPD proteins, detectable as 
early as 48-hours post transfection. Transfection of KLHL9 into both SF210 and 
SF763 also revealed a more robust growth phenotype than those we were able 
to obtain from the original SF210 cell line. Transient transfection of the lenti-
KLHL9 construct for 24 hours resulted in almost complete cell growth arrest and 









Exogenous expression of KLHL9 in two new aliquots of human-derived 
GBM cell lines (the original SF210 and a newly verified line SF763) 
provided by UCSF results in the loss of CEBPB and CEBPD proteins 
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Additionally, our collaborator Michael 
Berens provided access to a series of 
huGBM primary tumors that were 
passaged as xenografts in mice. 
These tumors were grown in a much 
more in vivo biological context than 
immortalized cell lines maintained in 
petri dishes without feeder cells, and 
provided an ideal model to address 
reviewer requests of in vivo experiments. 
Through qPCR of both cDNA transcripts 
and genomic DNA, we successfully identified two primary tumor grafts that 
exhibited evidence for a homozygous deletion of KLHL9, designated GBM64 and 
HF2354. 
 
Lentiviral infection of our KLHL9 construct and subsequent selection via 
Blasticidin in these contexts mirrored our observations in cell lines SF210 and 
SF763. Michael Berens’s group reported complete arrest following Blasticidin 
selection of both tumors when KLHL9 was introduced, but not when the RFP 
control vector was stably integrated. This work is currently ongoing and no data 
has been made available at the writing of this thesis. 
 
 
Transient transfection of a constitutive 
KLHL9 for 48 hours in both cell lines, SF210 
and SF763, resulted in a marked decrease in 
cellular prolifleration and increased number 
of dead or dying cells 
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CHAPTER 6 – Discussion of Results both Computational and Biological, 

























The technological advancements in generating human-derived, genome-wide 
panels of quantitative data have provided an extraordinary window into the 
complex genetic events that underlie the development and progression of 
cancers such as GBM. The ability to generate these comprehensive datasets 
across hundreds of patients is rapidly becoming a feasible, efficient means of 
acquiring data for analysis of human diseases, which immediately attaches 
translational relevance to experimental findings. However, the large, systemic 
genomic arrangements associated with cancers such GBM result in thousands of 
detectable genomic mutations or rearrangements, any combination of which 
could contribute to multiple biological and metabolic processes in a highly 
complex disease. An increasing challenge in the field of cancer research vis à vis 
the increase in high-throughput data acquisition is the development of methods 
to extract meaningful information from this sea of data. Furthermore, the already 
extensive knowledge of oncogenes and tumor suppressors has the unfortunate 
corollary of biasing research towards these well-known, well-characterized 
processes. While it has been reliably shown that multiple cancers share the 
same oncogenic pathways, this a priori selection bias inherently selects against 
the discovery of mutations that drive physiological behaviors independent of 
oncogenesis, which may nonetheless be vital to the understanding of the tumor. 
 
Instead, by creating and implementing a regulatory network approach we were 
able to identify two master regulators of the mesenchymal differentiation of GBM, 
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despite the fact that neither of these loci has ever been implicated in GBM 
before. Even further, our approaches were able to detect KLHL9 as a contributor 
specifically to mesenchymal differentiation despite the fact that it is highly linked 
to the most common oncogenic mutation in GBM: deletions of p16. We were able 
to accomplish this by integrating multiple genomic datasets and dynamically 
interrogating them directly for genes that were predicted to regulate the unique 
gene panel identifying mesenchymal GBM. 
 
DIGGIn is capable of highly accurate detection of functional genomic alterations. 
We successfully detected 14/18 bona fide oncogenes and tumor suppressors 
from a list of ~20,000 genomic loci at a statistically significant enrichment of 
p<1.93e-10. The number of genomic loci successfully identified as f-CNVs was 
only ~1500, or about 7.5% of the available loci. This result was surprising in the 
context of a disease with changes in whole chromosome arms, but coincides with 
the hypothesis that very few mutations would meaningfully contribute to the 
behavior of any given biological context. A relatively few number of genes are 
expressed in any tissue at a given time [ref], and genomic mutations affecting loci 
whose transcripts are not expressed should not be considered relevant to the 
disease. This was one of the primary purposes of devising DIGGIn: the 
elimination of gene loci from consideration based on biological evidence that they 
would be unrelated to the disease. This circumvents a prime limitation of 
genome-wide statistical studies: multiple hypothesis testing. Conversely, 
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biological relevance can be directly assigned to any genomic locus that passes 
the DIGGIn’s criteria. 
 
DIGGIn, ARACNe, and MINDy: fully parsing regulatory interactions 
When placed into the greater context of the systems biology methodologies 
developed in the Califano lab, DIGGIn occupies a complementary, but unique, 
niche in the full analytic framework. ARACNe and MINDy are algorithms 
designed to reverse-engineer a complete, comprehensive molecular network of 
transcriptional (ARACNe) and post-translational (MINDy) interactions.  From 
these networks, master regulators and modulators of master regulators can be 
inferred for a phenotype of interest, and this enriched set of genes can be 
subsequently interrogated for mutations. This approach adds an additional filter 
to circumvent the statistical power limitations that have traditionally stymied 
GWAS and other genome-wide analytics. Whereas these other methods must 
correct for multiple hypothesis testing on every gene expressed in the genome, 
or every gene tested for a mutation, ARACNe/MINDy-informed analysis is only 
concerned with a relatively small subset of genes that are computationally 
inferred to directly affect the phenotype being studied. 
 
DIGGIn, on the other hand, is designed specifically to identify genomic mutations 
and assign to them molecular perturbations, which may or may not be placed into 
the context of an interaction network. Rather than reconstructing a genome-wide 
interaction network and identifying master regulators to search for mutations, 
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DIGGIn identifies mutations and checks to see if they are candidate master 
regulators based on their perturbations. As a corollary, transcriptional and activity 
dependencies on candidate master regulators/drivers are made directly by using 
genomic reads rather than transcriptional reads of each candidate regulator. 
These intuitively minor distinctions have two major ramifications for the analysis 
that render DIGGIn unique from ARACNe/MINDy.  
 
First, DIGGIn is designed to identify regulators in the context of genomic 
mutations present in the samples, not molecular regulators of a reconstructed,  
“general” context network. This means that the DIGGIn algorithm is primarily 
designed to identify genomic mutations that modulate the expression of target 
biomarker panels – the primary concern is to identify mutations that induce a 
phenotype measured by a biomaker panel, not to define a comprehensive master 
regulator list.  The mutations will be mutations of master regulators or 
modulators, but again, defining a comprehensive set master regulators is not the 
goal of DIGGIn. DIGGIn can subsequently be informed by ARACNe and MINDy 
network analysis to verify the results, as has been implemented in this thesis. As 
a corollary, although DIGGIn may be unable to comprehensively identify master 
regulators, any mutations in master regulators will be immediately identifiable as 
significant regulators, even if they were undetectable by ARACNe/MINDy and 





Secondly, as a direct corollary of the first difference, the use of genomic data in 
one dimension of the mutual information analysis drastically alters the underlying 
map of the probability surface used in estimating mutual information. Gold 
standard and validated genomic loci that bear CNVs show excellent correlation 
with gene expression. This shows that genomic CNVs are excellent predictors of 
differential expression, and in these cases will produce similar estimates of 
mutual information regardless of whether genomic or gene expression data is 
used as long as the kernels are properly selected. The difference in 
performance of DIGGIn in these contexts is not an increase or decrease of 
the estimates of MI for a given gene-gene pair, but rather in the ranking of 
the MI estimate. As defined in the DIGGIn chapters, the null distribution of 
mutual information is defined by randomized pairing of genomic and gene 
expression vectors. This is done to generate a simulated set in which genomic 
mutations and genetic expression are entirely independent. When using 
exclusively gene expression data, there is a significant range of background 
noise generated by artificial correlations or indirect effects of expression. It is 
very likely that a significant set of genes that have no common regulator will be 
correlated with each other. This generates a null distribution with a relatively 
significant level of background noise, and can lead to complications with the 
application of DPI, or in the detection of modulating interactions that are real, but 




Conversely, the variance in genomic reads when samples are not mutated is 
extremely low. Any potentially real interaction between a genomic locus and 
gene expression will be immediately and significantly ranked above any genomic 
loci that do not bear mutations at all, simply because the coefficient of variance is 
significantly greater when mutations in the patient cohort exist. This immediately 
removes any possibility of genomic variance clouding real signals. The primary 
concern of DIGGIn then becomes parsing true signals out of LD blocks, which is 
detailed extensively in DIGGIn, part II. 
 
Combined, these two differences allow DIGGIn to detect biologically 
relevant regulators and modulators from genomic data. The gene KLHL9 
was not identified as a master regulator for GBM mesenchymal induction by the 
ARACNe algorithm, nor did was MINDy immediately able to identify it as a post-
translational modulator. Initial analysis with ARACNe yielded no information on 
KLHL9 because KLHL9 is not a transcription factor, and subsequent analysis on 
a subset of signal transduction molecules including KLHL9 failed to identify it as 
a significant master regulator. MINDy, on the other hand, was able to identify 
KLHL9 as a modulator locus only after we explicitly searched for KLHL9 as a 
candidate modulator. Even then, the locus would not have come up as a 
significant modulator of the CEBP master regulators in a blind, genomic analysis 
based, again, on enrichment ranks or p-value. The locus, while statistically 
significant, would not have appeared as a significant candidate modulator among 
the hundreds of modulators that are identified by MINDy. Yet, KLHL9 is clearly 
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an important modulator of the activities of CEBPB and CEBPD, as evidenced by 
my biological experiments with the gene. The deletion is significantly enriched in 
differential expression of the MES marker panel as a whole, and the activities of 
the master regulators CEBPB and D are significantly increased when KLHL9 is 
deleted (as inferred by the enrichment of each of the master regulator’s predicted 
regulons in the KLHL9 genomic-genetic hub). 
 
DIGGIn is able to detect these loci explicitly because its regulatory inferences are 
drawn from genomic-genetic data compared to genetic-genetic data.  
 
Conversely, DIGGIn’s primary weakness is the strength of ARACNe and MINDy. 
DIGGIn cannot detect master regulators or modulators if their respective 
genomic loci do not bear mutations. It is strictly designed to identify the driver 
mutations that both affect master regulators and modulators and exist in the 
samples being studied. What this means is that DIGGIn cannot detect or predict 
interactions between genes contributing to the development of a phenotype that 
do not bear mutations. ARACNe and MINDy interactomes provide interaction 
maps of hundreds of genes. These interactions can be detected across a swath 
of samples regardless of whether or not the genes involved bear mutations. 
These interactions can subsequently be used to explore the full extent and 
breadth of potential interactions for the development of treatments, predicting key 
mutations, and general abstractions of how a given disease is regulated. DIGGIn 
is designed to identify the functional mutations that exist in patients, 
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ARACNe/MINDy is designed to identify all genes that could affect the patients if 
they were to be mutated. 
 
The end result is that DIGGIn provides a valuable complementary perspective to 
ARACNe/MINDy. The use of genomic information as a proxy for one dimension 
of transcriptional information can be used to identify both mutations that directly 
exist in patients that affect a molecular phenotype, and master regulators or 
modulators that are not detectable by ARACNe and MINDy due to technical 
limitations specific to using transcription-only inferences.  
 
Modularity of DIGGIn and Application to Other Models 
As an analytic algorithm, the genetic-genomic analysis was implemented 
specifically with modularity in mind. GBM was selected as a prototype model for 
the development of these approaches primarily because of the availability of 
patient-matched datasets made available by the TCGA. However, these methods 
are applicable to the study of any genetic disease in which stable molecular gene 
expression profiles and accurate regulatory networks can be generated. This 
approach is directly applicable to any biological context in which the following 
criteria are met: The traits being studied are primarily caused by genetic 
contributions, genomic and gene expression arrays are obtainable, and the 





The algorithm is also set up in a framework that allows for the inclusion of 
additional metrics to define copy-neutral genomic alterations and assign to them 
functional molecular changes. Although they have not been implemented, 
analytic modules can be added to the framework to account for genomic and 
epigenetic events such as methylation and point mutations – any genomic event 
that can be detected by experimental methods on a genome-wide scale could 
theoretically be integrated into this analysis. For GBM, these extra metrics were 
deemed unnecessary to the scope of this thesis work because GBM is 
characterized primarily by copy number alterations, and because deep 
sequencing and methylation data was not available in format or in quantifies to 
allow for useful analysis.  
 
The identification of f-CNVs in these contexts are possible with as little as 80-100 
samples, although this presents the bare minimum required to achieve the 
needed statistical power. If these results are to be integrated with regulatory 
networks generated by methods such as ARACNe and MINDy, additional 
samples will be required to ensure accurate reconstruction of these regulatory 
networks, as outlined in [Margolin et al.]. However, the genetic-genomic analyses 
can be supplemented with any post-processing methods to add additional 
biological context to the results. 
 
Biological Relevance of Computational Findings 
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Using this integrative genetic-genomic approach, we were able to positively 
identify two candidate master regulators of the mesenchymal subtype without 
any a priori information of the molecular classification of the tumors. Of the two, 
CEBPD had already been validated as a mesenchymal master regulator, and we 
subsequently identified KLHL9 as a post-translational regulator of the CEBP 
master regulators of MES transformation. We were able to identify a post-
translational regulator of MES transformation in tight linkage disequilibrium with a 
common oncogene using only genomic and transcriptional data. In addition, we 
were able to positively identify almost the entirety of field-accepted bona fide 
tumor suppressors and oncogenes as f-CNVs; the only loci that were missed 
were ones that either were so rare that statistical power could not be reached 
(and indeed, these loci would not have been found by traditional methods in this 
dataset had they not already been established as oncogenes), or they were 
actively disregarded as functional because, although they may have been shown 
to induce oncogenesis in general, there was no evidence that these genes are 
expressed or functional in the context of GBM. 
 
These results demonstrate that the genetic-genomic approach is capable of the 
statistically enriched identification of biologically relevant genomic loci from a 
pool of tens of thousands of candidate mutated genomic loci, and thousands of 
genes expressed in GBM. Additionally, DIGGIn is capable of detecting the 
presence of multiple independent driver mutations that contribute to the etiology 
of a disease. This stands in contrast to traditional genomic approaches, which 
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are extensively limited in their detection power due to extensive hypothesis 
correcting, and due to the lack of dynamic partitioning. The accuracy of raw 
ANOVA or other statistic methods in a biological context deteriorates as the 
number of underlying genetic causes in a cohort increases, due to the presence 
of other causal genes polluting the association signal of any individual locus 
being tested. Whereas traditional statistical approaches are actively stymied by 
heterogeneity, DIGGIn was tailor-made with such biological contexts in mind and 
is actively designed to both circumvent and capitalize on the heterogeneity of the 
patient cohort.  
 
Implications of Biological Results (KLHL9) in GBM 
In the context of GBM specifically, this work provides significant evidence for the 
value of studying GBM, and cancers in general, not only in the context of 
oncogenesis and tumor progression, but also in a context that elucidates 
metabolic and physiological nuances that render tumors unique from patient to 
patient. This work and an increasing amount of gene expression studies in 
cancer show that the umbrella categories of cancer that have been traditionally 
assigned to tumors do not capture the diversity of the disease, even in relatively 
specific contexts such as glioblastoma, or astrocytoma[14][16][21]. Tumors under 
most of these classifications are still separable into distinct molecular subtypes 
based on their gene expression profiles, and it is possible to use these 
methodologies to elucidate molecular programs that associate with behaviors 
unique to specific subtypes. These unique molecular programs are functionally 
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distinct, but occur in tandem with the molecular changes associated with tumor 
development and progression, the classical field of cancer study. Subsequent 
application of regulatory networks allowed us to further identify that the entire 
signature could be regulated via a relatively small number of master regulators 
and showed that manipulation of these other molecular programs independent of 
classical oncogenic pathways could be sufficient to inhibit tumor growth. 
 
This work adds a complementary approach to the identification of master 
regulators by identifying the actual mutations that occur in tumor samples to alter 
the behavior of the master regulators, rather than inferring them from gene 
expression data. Based on the observation that large molecular panels can be 
manipulated by a small number of regulators, we were able to devise a 
computational framework to identify genomic events that showed evidence for 
perturbing the master regulators, instead of searching on a candidate-by-
candidate basis for involvement in classical cancer pathways or by a genome-
wide statistical study. This work allowed us to specifically target and identify the 
regulators of a specific molecular behavior in GBM with clinically relevant effects. 
The combination of network analysis and genetic-genomics allows for an 
approach that capitalizes on the information density of these large scale datasets 
without being hampered by statistical threshold limitations, and allows a focused 
approach to studying genome-wide molecular behavior using a small number of 




The identification of KLHL9 as a completely novel post-translational regulator of 
mesenchymal differentiation in GBM came directly as a computational prediction 
from exclusively human-derived data, which we subsequently validated with 
biological experimentation. Our integrative methods were able to identify this 
locus as a candidate master regulator despite it being deleted in “only” ~30% of 
mesenchymal tumors in our TCGA cohort, and despite it being in close proximity 
to the oncogene, p16. DIGGIn in its current implementation is not capable of 
detecting focal (promoter deletions), copy neutral (point mutations / frameshifts), 
or epigenetic (methylation) changes. We hypothesize that it is very likely that the 
remaining mesenchymal samples bear these undetected mutations in KLHL9, 
the master regulators themselves, or other upstream components that regulate 
the master regulators. Additionally, most genomic loci proximal to classical 
oncogenes are actively disregarded as contributory to tumor etiology in any way 
because they are assumed to be an artifact of association to those oncogenes. 
We were, instead, able to provide evidence that the high frequency of 
Mesenchymal tumors, which consist of over 50% of tumors obtained from the 
TCGA, is due to the high likelihood of obtaining losses of chromosome 9 that 
would span both p16 and KLHL9. This mutation would be sufficient to induce 
both tumorigenesis and mesenchymal transformation, and the development of 
mesenchymal GBM comes as a result of the simultaneous activation of at least 




As the rapid advances in biotechnology continue to produce vast amounts of 
genetic and genomic data at decreasing cost, a primary concern and field of 
research is the development of computational methods to meaningfully process 
this data in a biological context. Systems biological approaches have provided a 
novel perspective on the modeling of complex genetic traits and diseases, 
capitalizing on the availability of genomic data. The ability to infer regulatory 
networks has allowed us to integrate years of genetic research into a framework 
to understanding how large, modular molecular programs are regulated in cell-
specific contexts. 
 
Concurrently, it is becoming increasingly apparent that diseases as complex as 
cancer should not and cannot be addressed simply as a function of oncogenic 
behavior. Individual tumors can acquire multiple mutations in addition to 
oncogenic drivers that nonetheless can drastically alter the physiology of the 
tumor with very real clinical ramifications. These other mutations and their effects 
cannot be simply dismissed in the interest of studying oncogenesis or 
angiogenesis. The difference between mesenchymal and proneural GBM is a 
significantly shorter prognosis - mesenchymal patients in the TCGA cohort do not 
survive beyond 36 months post-diagnosis, while even proneural patients who 
succumb to the disease can still survive beyond 60-80 months (surviving patients 
are predominantly patients with proneural tumors and were not included in the 
TCGA cohort). The characterization of how these mutations affect the behavior of 
the tumor via their individual molecular programs not only broadens our 
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understanding of the disease, but also opens up new avenues of research for 
treatment. Conventional therapeutics that prove ineffective for certain cancers 
could potentially be replaced by more targeted agents that select against 
physiological behaviors unique to the cancer subtype, and increasing diagnostic 
panels to include cancer subtyping can grant valuable insight into improving the 
diagnosing of the disease. 
 
The goal of this work was to bridge the gap between these two rising issues and 
elucidate the genetic architecture of mesenchymal tumors in Glioblastoma 
multiforme. We have successfully created the computational methodology, 
DIGGIn, to predict driver mutations for individual molecular programs directly 
from human data. We were able to parse out and identify KLHL9, a novel, highly 
prominent post-translational regulator of mesenchymal differentiation in GBM. 
We were able to identify deletions of this gene as a functional genomic 
perturbation without any a priori information as to its relevance to GBM, and were 
subsequently able to predict its functionality in subtype differentiation out of 
hundreds of thousands of candidate loci, and to biologically identify its 
mechanism of action experimentally. Furthermore, the analytic rational and 
software architecture are readily applicable to any biological context that is 
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open(IN,"/Users/SupernerdMkII/Desktop/EUC classifier data/classifiers3.tab") or die; 
while(<IN>){ 












open(IN,"list3.tab") or die; 
#open(IN,"/Users/SupernerdMkII/Desktop/whole tumor expression 
sets/rembrant_data.exp") or die; 
while(<IN>){ 






# print $array[0]."\n"; 
  
 foreach $hub(@hubs){ 
  chomp $hub; 
  @hub=split/\t/,$vector{$hub}; 
  $vector="vector"; 
  $distance{$hub}=EUCDIST(\@array,$vector{$hub}); 
  push(@distances, $distance{$hub}); 
   
  print "$hub\t$distance{$hub}\t"; 
 } 
  
# print "$array[0]\t@distances\n"; 
  
 @distances = sort {$a<=>$b} @distances; 
 $min=$distances[0]; 
  
 foreach $hub(@hubs){ 
  if($distance{$hub}==$min){$classy=$hub;} 
 } 
  








 my @array1=@$arrayref; 
 my @array2=split/\t/,$coord; 
  
 my $eucd=0; 
  
 foreach $i(1..scalar(@array1)-1){ 




















































$thresh=0.168; #threshold of CNV reads to call amp or del 
 
open(IN,"<list1.tab") or die; 
while(<IN>){ 
 chomp $_; 
 $candidates{$_}=1; #defined as hash to extract exact CNV vectors from later 
arrays 
 $defined{$_}=0;  #defined to mark genes whose comparisons have 




@candidatekeys=keys(%candidates); #defined for the actual pairwise checking 
 
print "Candidates read.\n"; 
 
open(IN, "<wholeCNVsgenesonly.tab") or die; #cnv matrix file 
while(<IN>){ 









print "CNV vectors read.\n"; 
 
open(OUT, ">pairwise CNV results2.tab") or die; 
 
foreach $gene(@candidatekeys){ 
 print "$gene START\n"; 
  
 foreach $gene2(@candidatekeys){ 
   
  ## do not compare a gene against itself, and do not repeat comparisons 
that have already been done 
  next if($gene eq $gene2); 
  next if($defined{$gene2}==1); 
 
  ## define/reset counters 
  $Aamp=0; 
  $Bamp=0; 
  $Camp=0; 
  $Damp=0; 
   
  $Adel=0; 
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  $Bdel=0; 
  $Cdel=0; 
  $Ddel=0; 
   
  @array1=split/\t/,$candidates{$gene}; 
  @array2=split/\t/,$candidates{$gene2};   
 
  foreach $i(1..scalar(@array1)-1){ 
   #check AMP 
   if($array1[$i]<=-$thresh and $array2[$i]<=-$thresh){ $Aamp++; } 
   elsif($array1[$i]<=-$thresh and $array2[$i]>-$thresh){ $Bamp++; } 
   elsif($array1[$i]>-$thresh and $array2[$i]<=-$thresh){ $Camp++; } 
   elsif($array1[$i]>-$thresh and $array2[$i]>-$thresh){ $Damp++; } 
   
   #check DEL 
   if($array1[$i]>=$thresh and $array2[$i]>=$thresh){ $Adel++; } 
   elsif($array1[$i]>=$thresh and $array2[$i]<$thresh){ $Bdel++; } 
   elsif($array1[$i]<$thresh and $array2[$i]>=$thresh){ $Cdel++; } 
   elsif($array1[$i]<$thresh and $array2[$i]<$thresh){ $Ddel++; } 
 
  } 
   
  $pamp=PValue($Aamp,$Bamp,$Camp,$Damp); 
  $pdel=PValue($Adel,$Bdel,$Cdel,$Ddel); 
   
#  if($gene eq "ECHDC3"){ print 
"$gene2\t$Adel\t$Bdel\t$Cdel\t$Ddel\n"; } 
   















  $lnn+=log($n); 
  $n--; 
 } 
  






#Probability of one table 
############### 
sub ProbTable{ 
 my ($a , $b , $c, $d) = @_; 
 my $n = $a + $b + $c + $d; 
 my $LnNumerator     = LnFactorial($a+$b)+ 
                        LnFactorial($c+$d)+ 
                        LnFactorial($a+$c)+ 
                        LnFactorial($b+$d); 
 
 my $LnDenominator   = LnFactorial($a) + 
                        LnFactorial($b) + 
                        LnFactorial($c) + 
                        LnFactorial($d) + 
                        LnFactorial($n); 
 
  my $LnP = $LnNumerator - $LnDenominator; 







 my ($a, $b, $c, $d) = @_; 
  
 my $n = $a + $b + $c + $d; 
 
 my $p = 0; 
  




# if($a*$d >= $b*$c){ 
  $min = ($c < $b) ? $c : $b; 
  $i=0; 
   
  while($i<=$min){ 
   $a++; 
   $b--; 
   $c--; 
   $d++; 
       
   $p+=ProbTable($a,$b,$c,$d); 
   $i++; 
  }  
  if($p>1){$p=1;} 
   
































($exp,$cnv,$out,$m,$b, $FDR)=@ARGV; #input filepaths 
chomp $exp; #gene expression matrix 
chomp $cnv; #CNV matrix 
chomp $out; #base name of results file (statistics such as the kernel used will be 
appended to this) 
chomp $m; #slope of linear fit of function -log(p) null distribution 
chomp $b; #intercept of linear fit of function -log(p) null distribution 
chomp $FDR; #desired FDR threshold 
 
# parameters for NBL p-value estimation: derived from linear fit of -log(pnull) 
# $m = 12.22 
# $b = 0.4545 
 
# new NBL set 
# $m = 20.654 









######################## ACQUIRE DATA ######################### 
################################################################## 
 
## NOTE ## 
## This script is hardcoded to accept tab-delimited files with the first row 
## and column corresponding to the gene names and patient IDs, respectively. 
## These IDs must match in formatting across the exp and cnv files, but do NOT 
## have to be matched in order. 
 
## This stage of the script indexes all of the information contained in both the 
## CNV and expression files using a multi-dimensional hash. From here in, all data 
## for the analysis can be dynamically called from the hashes stored in memory, 
allowing 
## for maximum computational efficiency 
 
## input a file with <geneID> <expression vector> 
open(IN, "<$exp") or die; 
while(<IN>){ 




  foreach $i(1..scalar(@array)-1){ 
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   $expressionnameposition{$array[$i]}=$i-1; #first entry will not be in 
the vectors 
  } 




  $string=join("\t",@array[1..scalar(@array)-1]); 








print "Expression array finished.\n"; 
 
## input a CNV file <genename> <CNVvector> 
open(IN,"<$cnv") or die; 
while(<IN>){ 




  foreach $i(1..scalar(@array)-1){ 
   $cnvnameposition{$array[$i]}=$i-1; #first entry will not be in the 
vectors 
  } 
   




  $string=join("\t",@array[1..scalar(@array)-1]); 
  $geneCNVvector{$array[0]}=$string; 


















## This stage of the script is the active analysis of identifying functional f-CNVs 
## Each gene locus's cnv and expression vectors are retrieved and the MI between 
these 
## is computed. If the MI value passes the specified FDR, it is flagged as an f-CNV, 
## but no second-degree analysis is conducted yet. This module will output a list of 
## f-CNVs. The user can then allow the script to proceed or break this output list into 






print "***Defining fCNVGs***\n"; 
 
foreach $gene(@genes){ 
 chomp $gene; 
   























 if($fCNVtest{$gene}<=$q){  








open (OUT, ">$out"."_k_".$kernel."_FDR_".$FDR."_uncharacterized.tab") or die; 
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foreach $gene(@FCNVGs){ print OUT "$gene\t$fCNVtest{$gene}\n"; } 
close OUT; 
 
print "***".scalar(@FCNVGs)." fCNVGs defined. Characterizing.***\n"; 
 
 
################################ characterize fCNVGs 
 
## This stage of the script takes the results from the previous analysis and recurses, 
## measuring the MI between the CNV vector of the fCNV locus and the expression of 
## every gene in the genome. 
## This results in the linking of genes whose expression shows significant correlation by 
MI 
## to the mutational state of the fCNV, and is therefore potentially regulated by the fCNV 
 
 
open(OUT, ">$out"."_k_".$kernel."_FDR_".$FDR.".tab") or die; 
 
select((select(OUT),$|=1)[0]); #flush writing to OUT so that log can be checked 
 
foreach $gene(@FCNVGs){ 






 foreach $gene2(@genes){ 
  chomp $gene2; 
  next if($gene eq $gene2); 
   
  @EXPvector=split/\t/,$geneexpressionvector{$gene2}; 




   
  $p= 10**-($m*$MI+$b); 
   
  push(@pvalues,$p); 
   







 foreach $temp(@keys){ 
  if($target{$temp}<=$q){  
   $string=$string.$temp."\t".$target{$temp}."\t";  
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  } 
 } 
 











 my @CNV=@$CNVref; 
 my @exp=@$expref; 
  
 my @samplekey=keys(%{$expnames}); 
  
 my $xo; 
 my $yo; 
  
 my $top; 
 my $bottom; 
  
 my $MI=0; 
 my $topsum=0; 
 my $bottomsum1=0; 
 my $bottomsum2=0; 
 my $bottomtotal=0; 
  
 my $M=0; 
  
 foreach $sample(@samplekey){ 
  next if(defined(${$CNVnames}{$sample})==0); 
  $xo=$CNV[${$CNVnames}{$sample}]; 
  $yo=$exp[${$expnames}{$sample}]; 
  $topsum=0; 
  $bottomsum1=0; 
  $bottomsum2=0; 
     
  $M=0; 
   
  foreach $sample2(@samplekey){ 
   next if(defined(${$CNVnames}{$sample2})==0); 
   next if($sample2 eq $sample); 
   $M++; 






   $bottom1=MARG($xo, $CNV[${$CNVnames}{$sample2}] , 
$kernel2 ); 
   $bottom2=MARG($yo, $exp[${$expnames}{$sample2}] , $kernel2 
); 
       
   $topsum+=$top; 
   $bottomsum1+=$bottom1; 
   $bottomsum2+=$bottom2; 
 
  } 
    
  $topsum*=(1/$M)*((1/(2*3.14159*$kernel2**2))); 
  $bottomsum1*=(1/$M)*((1/(sqrt(2*3.14159*$kernel2)))); 
  $bottomsum2*=(1/$M)*((1/(sqrt(2*3.14159*$kernel2)))); 
   
  $bottomtotal=$bottomsum1*$bottomsum2; 
   
  # The following condition was added as a failsafe in the event that a zero 
value 
  # is somehow obtained from the bottom marginal functions (resulting in 
division by zero) 
  if($bottomtotal==0){ $bottomtotal=0.0000001; } 
   
  #calculate MI here 
  $MI+=(log($topsum/$bottomtotal)/log(10)); 
   
 } 
   
 $MI*=(1/$M); 
  




#join probability density function of 2 variables using Gaussian kernel 
sub JOINT{ 
 my($xo, $xi, $yo, $yi, $h)=@_; 
  
 my $joint = exp(-((($xo-$xi)**2+($yo-$yi)**2)/(2*$h**2))); 
  
 return $joint; 
} 
 
#marginal probability density function of a variable using Gaussian kernel 
sub MARG{ 
 my($xo, $xi, $h)=@_; 
  
 my $marg= exp(-((($xo-$xi)**2)/(2*$h**2))); 
  










 my $q=0; 
 my @scores = sort {$a<=>$b} @$arrayname; 
 my $m=scalar(@scores); 
  
 foreach $i(0..scalar(@scores)-1){ 
  my $k=$i+1; 
   
  if($scores[$i]<=(($k/$m)*$threshold)){ $q=$scores[$i]; } 
 } 
  

































































open(IN, "<$exp") or die; 
while(<IN>){ 




  foreach $i(1..scalar(@array)-1){ 
   $expressionnameposition{$array[$i]}=$i-1; #first two entries will 
not be in the vectors 
  } 




  $string=join("\t",@array[1..scalar(@array)-1]); 
  $geneexpressionvector{$array[0]}=$string; 








print "Expression array finished.\n"; 
 
open(IN,"<$cnv") or die; 
while(<IN>){ 






  foreach $i(1..scalar(@array)-1){ 
   $CNVnameposition{$array[$i]}=$i-1; #first entry will not be in the 
vectors 
  } 
   




  $string=join("\t",@array[1..scalar(@array)-1]); 





print "CNV array finished.\n"; 
 
############################################################ 
#################### NULLDISTRIBUTION #################### 
############################################################ 
 








 next if(defined($geneCNVvector{$genes[$int]})==0); 




 @expression=split/\t/,$geneexpressionvector{$genes[$int]};  
  




 print $information."\n"; 
 print OUT $information."\n"; 














 my @CNV=@$CNVref; 
 my @exp=@$expref; 
  
 my @samplekey=keys(%{$expnames}); 
  
 my $xo; 
 my $yo; 
  
 my $top; 
 my $bottom; 
  
 my $MI=0; 
 my $topsum=0; 
 my $bottomsum1=0; 
 my $bottomsum2=0; 
 my $bottomtotal=0; 
  
 my $M=0; 
  
 foreach $sample(@samplekey){ 
  next if(defined(${$CNVnames}{$sample})==0); 
  $xo=$CNV[${$CNVnames}{$sample}]; 
  $yo=$exp[${$expnames}{$sample}]; 
  $topsum=0; 
  $bottomsum1=0; 
  $bottomsum2=0; 
     
  $M=0; 
   
  foreach $sample2(@samplekey){ 
   next if(defined(${$CNVnames}{$sample2})==0); 
   next if($sample2 eq $sample); 
   $M++; 
       
   $top=JOINT($xo , $CNV[${$CNVnames}{$sample2}] , $yo , 
$exp[${$expnames}{$sample2}] , $kernel2); 
   $bottom1=MARG($xo, $CNV[${$CNVnames}{$sample2}] , 
$kernel2 ); 
   $bottom2=MARG($yo, $exp[${$expnames}{$sample2}] , $kernel2 
); 
       
   $topsum+=$top; 
   $bottomsum1+=$bottom1; 
   $bottomsum2+=$bottom2; 
 
  } 
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  $topsum*=(1/$M)*((1/(2*3.14159*$kernel2**2))); 
  $bottomsum1*=(1/$M)*((1/(sqrt(2*3.14159*$kernel2)))); 
  $bottomsum2*=(1/$M)*((1/(sqrt(2*3.14159*$kernel2)))); 
   
  if($topsum ==0) { $topsum=0.0000001; } 
   
  $bottomtotal=$bottomsum1*$bottomsum2; 
   
  if($bottomtotal==0){ $bottomtotal=0.0000001; } 
   
  #calculate MI here 
  $MI+=(log($topsum/$bottomtotal)/log(10)); 
   
 } 
   
 $MI*=(1/$M); 
  




#join probability density function of 2 variables using Gaussian kernel 
sub JOINT{ 
 my($xo, $xi, $yo, $yi, $h)=@_; 
  
 my $joint = exp(-((($xo-$xi)**2+($yo-$yi)**2)/(2*$h**2))); 
  
 return $joint; 
} 
 
#marginal probability density function of a variable using Gaussian kernel 
sub MARG{ 
 my($xo, $xi, $h)=@_; 
  
 my $marg= exp(-((($xo-$xi)**2)/(2*$h**2))); 
  










































open(IN, "<wholeCNVsgenesonly.tab") or die; 
while(<IN>){ 
 chomp $_; 
 @array=split/\t/,$_; 
 
 #hash tcga sample labels (sample name as keys, position as variable)  
 if($initial==0){ 
  foreach $i(1..scalar(@array)-1){ 
   $CNVaddress{$array[$i]}=$i; 
  } 




 #hash CNV vectors (gene name as key, entire string as variable)  
 else{ 





#CNVaddress hash = addresses 





open(IN, "<gene_in_network_expression.exp") or die; 
while(<IN>){ 
 chomp $_; 
 @array=split/\t/,$_; 
  
 #hash tcga sample labels again (sample positions as keys, labels as variable 
 if($initial==0){ 
  foreach $i(2..scalar(@array)-1){ 
   $EXPaddress{$i}=$array[$i]; 
  } 




  @expression2=(); 
 
  next if(exists($CNVvector{$array[1]})==0); 
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  #for each gene, push expression into an array and hash the expression 
(key) to the sample (address) 
  foreach $i(2..scalar(@array)-1){ 
   push(@expression2, $array[$i]); 
   $EXPvector{$array[$i]}=$i; 
  } 
   
  #call and array CNV vector of same gene 
  @CNVrefarray=split/\t/,$CNVvector{$array[1]}; 
     
  for ($i=scalar(@expression2)-1; $i>=0; $i--){ 
  
 if(defined($CNVaddress{$EXPaddress{$EXPvector{$expression2[$i]}}})==0){ 
    splice(@expression2,$i,1); 
   } 
  } 
     
  #reorder expression array ascending 
  @expression=sort {$a <=> $b} @expression2; 
     
  #define 3 variables: amp del norm, initialize to zero  
  $amp=0; 
  $del=0; 
   
  $ampcount=0; 
  $delcount=0; 
  $normcount=0; 
   
  @amparray=(); 
  @delarray=(); 
   




       
   if($CNVvalue >= $CNVthreshold){  
    push(@delarray,$expression[$i]); 
   } 
    
   elsif($CNVvalue <= -$CNVthreshold){      
    push(@amparray,$expression[$i]); 
   } 
    
   else{ 
    push(@delarray,$expression[$i]); 
    push(@amparray,$expression[$i]); 
    $normcount++; 
   } 
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  } 
   




    
   if($CNVvalue <= -$CNVthreshold){$amp+=($i+1); $ampcount++;} 
  } 
   




    
   if($CNVvalue >= $CNVthreshold){$del+=($i+1); $delcount++;} 
  } 
   
  $UscoreAMP=$amp - ($ampcount * ($ampcount+1))/2 ; 
  $UscoreDEL=$del - ($delcount * ($delcount+1))/2 ; 
   
  $Uampmax=$ampcount*$normcount; 
  $Udelmax=$delcount*$normcount; 
   
  if($UscoreAMP < $Uampmax/2){ $UscoreAMP=$Uampmax-
$UscoreAMP; } 
   
  $zAMP=NullDist($ampcount,$normcount, $UscoreAMP); 
   
  print "$array[1]\t$ampcount\t$zAMP\n"; 










 my $total=$n1+$n2; 
 my @Uray=(); 
 my @n1=(); 
  
 #print "$n1\t$n2\t$U\n"; 
 my $trials=5000; 
 #$count=0; 
  
 foreach $i(1..$trials){ 
  my $temp=$total; 
  my @n2=(0..$total); 
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  #print "entering first loop\n"; 
  while(scalar(@n1) <= $n1){ 
   my $int=int(rand($temp-1))+1; 
    
   push(@n1,$n2[$int]); 
   splice(@n2,$int,1); 
   $temp--; 
  } 
  
  my $sum=0; 
  
  foreach $entry(@n1){ 
   $sum+=$entry; 
  } 
  
  $U=$sum-(scalar(@n1) * (scalar(@n1)+1)/2); 
  
  if($U < $n1 * $n2 - $U){ $U = $n1 * $n2 - $U;} 
  
  push(@Uray,$U); 
  @n1=(); 
 } 
 
 my $average=0; 
 
 foreach $entry(@Uray){ 





 my $stdev=0; 
 
 foreach $entry(@Uray){ 





 #print "$n1\t$n2\t$average\t$stdev\n"; 
  
 my $z=($Ufound-$average)/$stdev; 
 @Uray=(); 







APPEND05 – Manuscript Figures and Figure Legends 
Figure1.  
(a) 1 Network map showing co-mutated f-CNVG loci as a function of the 
statistical associations of genes harboring amplifications (blue nodes) or 
deletions (red nodes). Edges denote a statistically significant association 
between connected f-CNVGs ascertained by Fisher Exact’s Test (FET) (p < 0.05 
Bonferroni corrected). The connected nodes’ clustering distance is also based on 
strength of association i.e. juxtaposed nodes are more significantly associated to 
each other than distantly connected nodes. Chromosome location for the larger 
clusters, and the location of the C/EBP" and KLHL9 nodes are provided. (b) 483 
loci were identified as bearing functional CNV genes (f-CNVG). Presented is a 
statistical summary of associations of the f-CNVGs passing these criteria to the 
poor-prognosis subtype versus the good-prognosis subtype, including “classical” 
oncogenesis f-CNVGs. Marks indicate amplifications (+) deletions (-) and diploid 
(WT) for each gene.   
 
Figure2. 
(a) The f-CNVGs statistically co-occurring with amplifications of C/EBP" or 
deletions of KLHL9, and associated with the poor prognosis phenotype across all 
TCGA samples were retrieved from the f-CNVG association network from Figure 
1a (amplifications as blue nodes, deletions as red nodes, edges denoting 
significant association). Each f-CNVG in the cluster for C/EBP" (b) or KLHL9 (c) 
was then conditionally tested in pair-wise fashion for association to the poor 
prognosis subtype; color grading corresponds to the -log(p) of the association 
(white cells indicate p > 0.1) of the tested locus (rows) to the poor prognosis 
phenotype upon conditioning for the absence of the indicated, conditioned locus 
(columns). I.e., conditioning on KLHL9 abrogates the association of all other f-
CNVGs in its cluster to the poor-prognosis phenotype (white column), while only 
one locus can abrogate association of KLHL9 (red row). Only KLHL9 and 
C/EBP" (indicated in bold and boxed in) remove all associations across their 
respective co-mutated clusters when conditioned for, yet remained robust to 
conditioning on the other genes in the cluster. The average -log(p) value 
associated with each conditioned locus across all tested loci is provided in the 
last row of each heatmap. 
 
Figure3. 
(a) Genomic q-PCR analysis of an independent cohort of 63 patients reveals a 
high enrichment of KLHL9 deletions in patients with poor prognosis. y-axis is 
reported in CT values with the cutoff for statistically significant evidence of a 
deletion presented as a red line; all CT values above the red line indicate 
evidence of deletion. CT values are reported as mean ±SEM (b) Statistical 
analysis of the results presented in Figure 3b shows a highly significant 
association of samples bearing a KLHL9 deletion to the poor prognosis cohorts. 
(c) Kaplan-Meier curves of patients based on their genotype at the KLHL9 and 
CEBPD loci. x-axis represents post-diagnostic survival in months, y-axis the 
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percentage of patients surviving at measured time points. The presence of 
C/EBP" amplifications and KLHL9 deletions in patient samples (red line) is 
sufficient to separate poor prognosis from good prognosis patients in GBM TCGA 
samples, as defined by expression of PN signature markers (black line), and 
even compared to pooled Good and Poor prognosis samples lacking those 
mutations (blue line) at a statistically significant level (p1 = red vs. blue, p2 = red 
vs black, alpha=0.05). Distribution of prognoses of individual patients with tumors 
bearing the C/EBP" amplification (C/EBP"+) and KLHL9 deletions (KLHL9-) are 
indicated as hashes in the labeled boxes below the graph. Hashes note the time 
of death after diagnosis of each patient bearing the corresponding mutation 
across all samples. (d) IHC probing for CEBPB and CEBPD proteins in these 
primary tissue samples reveals a strong correlation between elevated CEBP 
expression in GBM tumors and the MES subtype, as well as a significant 
association to KLHL9 deletions. 
 
Figure4. 
Effect of KHLH9 expression on C/EBP!/" and YKL40 mRNA and protein levels 
96 hours post-induction. (a) KHLH9 mRNA expression levels by qPCR in the two 
inducible KHLH9 clones and GFP control cells. (b) RNAseq analysis of these 
cells after 48 hours of induction reveals significant dysregulation in ARACNE-
predicted transcriptional targets of C/EBP!, C/EBP", and a significant 
reprogramming away from the canonical MES subtype. Benchmark 
mesenchymal markers are indicated on the barcodes for reference. No 
significant change in C/EBP! or C/EBP" expession levels were observed (c) 
KHLH9, C/EBP!, C/EBP", and STAT3 protein levels 72h after Dox-mediated 




Protein half-life time course for C/EBP!/" conditioned on KLHL9 expression. 
Abbreviations: DOX = doxycycline, MG132 = proteasome inhibitor. (a) A 4-hr 
exponential time courses conducted for protein half-life in KLHL9-induced , 
KLHL9-induced-proteasome-inhibited, and GFP-induced SF210 cells with 
cyclohexamide treatment. Cells expressing KLHL9 in the presence of 
cyclohexamide showed a protein half-life of ~1hr for C/EBP!/" proteins that was 
not observed in GFP controls (>2hr half life). Addition of MG132 to KLHL9-
expressing cells restored the half-life of the CEBP proteins to those observed in 
the KLHL9-null GFP controls. (b) Co-immunoprecipitation of KLHL9 shows an 
interaction between KLHL9 and CEBP proteins (c) Immunoprecipitation of 
C/EBP! and C/EBP" proteins and probing for ubiquitylation reveals increased 
concentrations of poly-ubiquitylated CEBP proteins only when KLHL9 is 
expressed; conversely, precipitating ubiquitylated species and probing for CEBPs 
corroborates this observation. These IPs (in Figure 5c) were performed under the 







(a) A basic representation of the KLHL9 protein showing key functional domains, 
and the structure of the mutant KLHL9-#BTB. (b) Ubiquitin IPs of the three 
constructs following 24 hours of expression and 4 hours of MG-132 treatment 
shows suppression of ubiquitylated CEBP species when a mutant, inactive form 
of KLHL9 is used for rescue. (c) Western blotting of whole cell lysates after 48 
hours of exogenous expression of either KLHL9, KLHL9-#BTB, or NT.  
 
Figure7. 
(a) Induction of KLHL9 is followed by the appearance of large, circular cells with 
large nuclei, visualized by blue nuclear stain. These cells also do not incorporate 
EdU (red) when exposed to it over 24 hours, unlike the normal, fibroblast-like 
counterparts. Cells that do not incorporate EdU (and are therefore considered 
non-proliferative) have nuclei that appear blue in the composite image; arrows 
demarcate the nuclei of these cells. (b) Flow cytometry of BrdU incorporation by 
KLHL9-induced (red) and uninduced cells (black) after 24 hours of BrdU 
exposure is presented as histograms internally normalized to the highest peak. A 
BrdU negative control is provided (gray). Color-coded integrations for the area 
under the defined peaks are provided as left-peak : right-peak percentage ratios. 
(c) Cell viability measured as a function of ATP activity in KLHL9-expressing vs 
KLHL9-nonexpressing cells and GFP controls. Closed datapoints represent 
normalized cell proliferation in DOX-induced samples and open datapoints 

































































APPEND06 – Manuscript Supplemental Figures and Figure Legends 
SuppFigure1.  
(1a) Five hierarchically self-regulating transcription factors (C/EBP!/", STAT3, 
FOSL2, BHLHB2, and RUNX1) were identified as the master regulators of 
aggressive, poor prognosis GBM by the ARACNE algorithm. (1b) TCGA samples 
classified into “good” and “poor” prognosis using the activity of these five 
transcription factors in TCGA data shows a statistically significant separation in 
survival curves (p<0.05). 
 
SuppFigure2.  
Functional copy number variation genes (f-CNVGs) are defined as copy number 
variations in gene loci where differential expression of the gene is detected in 
correlation with the observed CNV. (2a) Nonfunctional CNVs will show no 
differential expression of host genes between amplified (red) and diploid (blue) 
samples. (2b) Functional CNVs show a measurable differential expression 
between amplified (red) and normal (samples). (2c) Measuring statistical 
dependencies between CNVs and gene expression via traditional statistical tests 
yields little statistical power, producing only 51 functional CNVs (U-test). In 
constrast, information theoretic approaches (Mutual Information) more than 
double the amount (124 total) of detectable dependencies at the tested 




The null distribution for measuring mutual information is empirically-determined 
by randomly pairing 10,000 CNV and gene expression vectors and measuring 
the mutual information between them, representing the mutual information 
obtained under the null hypothesis of random pairing (no correlation). A 
regression function is then fit to this distribution that is used to estimate the p-




Eight huGBM-derived cell lines assayed for deletions in the KLHL9 or CDKN2A 
CDS locus. y-axis represents normalized CTs; positive CTs indicate less 
genomic DNA present, and each CT represents a fold change of 2 relative to the 
control GAPDH levels, set at 0 CT. CT values are reported as mean ±SEM. Red 
line indicates threshold for statistically-significant evidence for genomic deletions. 
 
SuppFigure5. 
(5a) Probe mapping of the Affymetrix SNP arrays reveals lack of coverage of the 
C/EBP" gene locus (red hashes denote probes across different samples) and 
sparse coverage of the genomic region compared to CGH arrays. (5b) Probe-
wise association mapping of the chromosome 8 locus using Affy SNP arrays 
does not reveal significant association of the gene locus with poor prognosis as 
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reported by the CGH arrays. (5c) Using a sliding window integration, significant 
association of the C/EBP! locus is detected using Affymetrix arrays, though not 
as significantly as reported by CGH arrays. X-axes represent chromosome 
position in megabases, y-axis depicts odds ratios of association. 
 
SuppFigure6. 
Probes available in Affymetrix SNP arrays do not recapitulate the CNV;gene 
expression correlations observed when integrating the CGH arrays with gene 
expression profiles. The three maximally associated probes in the region, labeled 
as peaks -1,0, and +1, were each individually tested for correlation to the mRNA 
expression of C/EBP!; those probes were unable to predict mRNA levels with 
any significance. Integration of probes using a sliding window reveals a 
correlation with C/EBP! mRNA, but still with less information than the probes 
provided by the CGH arrays. 
 
SuppFigure7. 
Segmentation maps pre-GISTIC processing of the CEBPD and KLHL9 genomic 
loci were used to deconvolve the mutational topography for genetical-genomics 
analysis. GISTIC processing removes the CEBPD locus entirely as a false signal 
and renders deletions at the KLHL9 and CDKN2A loci as mutually inclusive and 
equivalent across all samples bearing deletions at CDKN2A. 
 
SuppFigure8. 
Association scores presented as –log10(p) on the y-axes. X-axes plot the location 
of each locus by megabase along the chromosomes. Gene names in red indicate 
genes harboring functional CNVs. Bolded gene names indicate genes expressed 
in the TCGA GBM tumors, and plain text indicate genes that are not expressed in 
TCGA GBM. Gene locations are indicated as diamonds. (7a) Probe-wise 
association mapping across the locus on chromosome 8 harboring C/EBPd 
reveals a focal amplification that associates with the poor-prognosis subtype (red 
line). When samples bearing C/EBP! amplifications are removed, the association 
across the region is also removed (blue line). Gene locations are indicated 
(diamonds). (7b) Probe-wise association mapping across the locus on 
chromosome 9 harboring KLHL9 reveals a deletion that associates with the MES 
subtype versus PN/PRO (red line) spanning ~21MB-22MB, including KLHL9 and 
CDKN2A. When samples bearing C/EBPd amplifications are removed, the 
association across the region is also removed (blue line).  (7c) At the KLHL9 
locus, removing all samples carrying a deletion of the CDKN2A locus but diploid 
at the KLHL9 locus enhances the association of the KLHL9 locus to the poor-
prognosis phenotype (blue line) compared to the complete set (red line). 
 
SuppFigure9. 
Transcriptional cross-talk experiments using siRNAs reveals regulatory 
interactions between the MES master regulators CEBPD and STAT3. STAT3 
silencing induces a reduction in transcription of CEBPD, placing CEBPD and 





Gene lists of genes bearing CNVs functionally correlating with MGES behavior (f-
CNVGs) are listed by their methods of identification: genetical genomics and 
MINDy modulator analysis. In addition, a list of commonly-used “classical” CNV 
markers of GBM oncogenesis are listed, and the genes whose CNVs were 
identified as f-CNVs by our genetical genomic analysis are represented in bold. 
All classical CNVs that were not identified appeared in fewer than 10 samples in 
the total TCGA set (<5% of samples). 
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